EHA / 14th Congress / Program overview per day / Friday Program
Poster Session
POSTER-WALKS
We would like to invite you to the EHA Poster sessions
Poster walks have been was introduced in order to gain a maximum benefit from the scientific work presented and to create a lively interaction and discussion between poster authors, moderators and interested delegates. Poster-walks will be organized during poster sessions on Friday, June 5 (17:45 – 19:00) and Saturday, June 6 (18:00 – 19:15). The poster area is located in Hall 12 and Hall 14.1. Poster-walk moderators can be recognized by their cap. We kindly ask you to be in time at the first poster in the poster session of your interest. Drinks and snacks will be served.
POSTER SESSION I
Poster presentation during Poster-walks from 17:45 – 19:00.
Poster Area (Hall 12 and Hall 14.1)
- DEVELOPMENTAL HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT
Poster-walk Moderator: T Lapidot (Weizmann Institute of Science, Rehovot, Israel)
- TRANSCRIPTIONAL CONTROL, EPIGENETICS, CELL CYCLE REGULATION AND APOPTOSIS
Poster-walk Moderator: B Simonsson (University Hospital, Uppsala, Sweden)
- GENOMICS AND PROTEOMICS & CYTOGENETICS AND MOLECULAR DIAGNOSTICS
Poster-walk Moderator: B Young (Institute of Cancer, London, United Kingdom)
- CYTOGENETICS AND MOLECULAR DIAGNOSTICS
Poster-walk Moderator: C Mecucci (Ospedale della misericordia, Perugia, Italy)
- CELLULAR IMMUNOTHERAPY AND VACCINATION
Poster-walk Moderator: F Falkenburg (University Medical Center, Leiden, The Netherlands)
- ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL
Poster-walk Moderator: R Pieters (Erasmus University Medical Center, Rotterdam, The Netherlands)
- HODGKIN LYMPHOMA
Poster-walk Moderator: A Engert (Klinikum der Universität, Keulen, Germany)
- BLEEDING DISORDERS (CONGENITAL AND ACQUIRED)
Poster-walk Moderator: J Ingerslev (University Hospital Skejby, Aarhus, Denmark)
- QUALITY OF LIFE, PALLIATIVE CARE AND ETHICS
Poster-walk Moderator: A Novik (Pirogov National Medical Surgical Center, Moscow, Russia)
- STEM CELL TRANSPLANTATION – GVHD, GRAFT REJECTION, INFECTION
Poster-walk Moderator: P Jakobs (Constantiaberg Medi-Clinic, Plumstead, South-Africa)
- STEM CELL TRANSPLANTATION – AUTOLOGOUS, DLI, MISCELLANEOUS
Poster-walk Moderator: J Passweg (Hopitaux Universitaires, Geneve, Switzerland)
- NOVEL THERAPEUTICS, TARGETED THERAPIES AND GENE THERAPY
- PRECLINICAL & CLINICALPoster-walk Moderator: A Hagenbeek (Academic Medical Center, Amsterdam, The Netherlands)
- RED BLOOD CELLS AND IRON I
Poster-walk Moderator: P Beris (Hôpital Cantonal Universitaire, Geneva, Switzerland)
- RED BLOOD CELLS AND IRON II
Poster-walk Moderator: J Porter (University College, London, United Kingdom)
- PLATELETS & THROMBOCYTOPENIA I
Poster-walk Moderator: C Gachet (Inserm-Université, Strasbourg, France)
- MYELODYSPLASTIC SYNDROMES I
Poster-walk Moderator: Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden)
- ACUTE MYELOID LEUKEMIA - BIOLOGY I
Poster-walk Moderator: C Chomienne (Hospital Saint Louis, Paris, France)
- ACUTE MYELOID LEUKEMIA - BIOLOGY II
Poster-walk Moderator: N Bolli (Dana-Farber Cancer Institute, Boston, USA)
- ACUTE MYELOID LEUKEMIA – CLINICAL I
Poster-walk Moderator: F Lo Coco (University Tor Vergata, Rome, Italy)
- CHRONIC MYELOID LEUKEMIA - BIOLOGY
Poster-walk Moderator: M Deininger (Oregon Health & Science University, Portland, USA)
- CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY I
Poster-walk Moderator: D Oscier (Royal Bournemouth, Bournemouth, United Kingdom)
- CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL I
Poster-walk Moderator: E Montserrat (Hospital Clínic, Barcelona, Spain)
- MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY I
Poster-walk Moderator: O Sezer (Charité - Universitätsmedizin Berlin, Berlin,
Germany) - MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL I
Poster-walk Moderator: A Waage (St. Olav University Hospital, Trondheim, Norway)
- NON-HODGKIN LYMPHOMA - CLINICAL I
Poster-walk Moderator: M Trneny (Charles University General Hospital, Prague, Czech Republic)
- NON-HODGKIN LYMPHOMA - CLINICAL II
Poster-walk Moderator: A Ferreri (San Raffaele H Scientific Institute, Milan, Italy)
- THROMBOSIS AND VASCULAR BIOLOGY I
Poster-walk Moderator: H Büller (Academic Medical Center, Amsterdam, The Netherlands)
- INFECTIOUS DISEASES, SUPPORTIVE CARE I
Poster-walk Moderator: G Maschmeyer: (Klinikum Ernst von Bergmann, Potsdam, Germany)
POSTER SESSION I
17:45 – 19:00
DEVELOPMENTAL HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT
| 0001 | RESCUE OF HEMATOPOIETIC FAILURE INDUCED BY THE GATA
1(LOW) MUTATION IS MEDIATED BY A PERMISSIVE MICROENVIRONMENT
IN THE SPLEEN THAT INDUCES DIFFERENTIATION
OF GATA -1(LOW) PROGENITORS THROUGH THE ALTERNATIVE
ENHANCER HS2 |
|---|---|
| 0002 | 0002 COMPARISON OF HEMATOPOIETIC STEM CELL (HSC) ENGRAFTMENT ON SYNGENEIC AND ALLOGENEIC STROMAL TERRITORIES IN THE ABSENCE OF IMMUNE REACTION |
| 0003 | THE EFFECT OF THE TEL-TRKC ONCOGENE ON THE HAEMATOENDOTHELIAL |
| 0004 | IFNA ACTIVATES DORMANT HSCS IN VIVO |
| 0006 | TYROSINE KINASE INHIBITION FAILS TO ERADICATE LEUKEMIC STEM/PROGENITOR CELLS IN FLT3-ITD+ ACUTE MYELOID LEUKEMIA: ROLE OF THE STEM CELL NICHE S. Götze, A. Parmar, S. Rushton, S.M. Marz, K. Lind, S. Kayser, K. Döhner, C. Peschel, R. Oostendorp (Technische Universität München, Munich, Germany) |
| 0007 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION PERTURBS MYELOID SUBLINEAGE DIFFERENTIATION BY INHIBITING PU.1 UPREGULATION S. Richter, P. Platzer, M. Woisetschlager, D. Waltenberger, H. Strobl (Institut of Immunology, Vienna, Austria) |
| 0009 | THE ROLE OF CYCLIN A1 AND APOPTOSIS IN MURINE HEMATOPOIETIC STEM CELLS E. Diffner, J. Liao Persson (Experimental Cancer Research, Malmö, Sweden) 14th CONGRESS |
| 0010 | INTEGRIN ALPHA9 CONTRIBUTES TO ADHESION AND DIFFERENTIATION OF HUMAN HEMATOPOIETIC STEM/- PROGENITOR CELLS IN THE HUMAN BONE MARROW G. Klein, C. Steinl, C.A. Müller, W.K. Aicher, T.D. Schreiber (University Medical Clinic Tübingen, Tuebingen, Germany) |
| 0011 | DIFFERENTIAL LOCALIZATION OF P-SELECTIN AND VON WILLEBRAND FACTOR DURING MEGAKARYOCYTE MATURATION M.K. Zetterberg, R.A. Rana, M. Zingariello, M.E. Fabucci, D. Bosco, A.R. Migliaccio, F. Martelli (Istitituto di sanità superiore, Rome, Italy) |
| 0012 | ASSESSMENT OF INDUCED BONE MARROW SUPPRESSION AND HEMATOPOIETIC GROWTH FACTORS ON HEPATIC REGENERATION AFTER PARTIAL HEPATECTOMY IN ALBINO RATS E.D.S. Alaa Abd El Hamid (Faculty of Medicine, Sue Canal University, Ismailia, Egypt) |
| 0013 | ISOLATION, DIFFERENTIATION AND NEUROPROTECTIVE PROPERTIES OF NEURONAL PROGENITORS FROM HUMAN UMBILICAL CORD BLOOD H. Arien-Zakay, P. Lazarovici, H. Galski, A. Nagler (Chaim Sheba Medical Center, Ramat-Gan, Israel) |
TRANSCRIPTIONAL CONTROL, EPIGENETICS, CELL CYCLE REGULATION AND APOPTOSIS
| 0014 | MAINTENANCE OF NORMAL HEMATOPOIETIC PROGENITOR CELLS BY THE DEACETYLASE INHIBITOR LAQ824 IS ASSOCIATED WITH INDUCTION OF NOTCH TARGET GENES |
|---|---|
| 0015 | THE TUMOR SUPPRESSOR GENE DISABLED-2 IS EPIGENETICALLY DOWNREGULATED IN MULTIPLE MYELOMA |
| 0016 | A DNASE I HYPERSENSITIVE SITE IN THE DISTAL PROMOTER REGION OF THE BCL-6 LOCUS BINDS ZEB1 AND IS RESPONSIBLE FOR TRANSCRIPTIONAL REPRESSION |
| 0017 | GENOME-WIDE IDENTIFICATION OF BINDING SITES OF EVI1 IN HUMAN MYELOID CELL LINES |
| 0018 | MICRORNA EXPRESSION PROFILES IN UMBILICAL CORD BLOOD CELL LINEAGES M. Merkerova, A. Vasikova, M. Belickova, H. Bruchova (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) |
| 0019 | RESTORATION OF RETINOIC ACID-TARGET GENE TRANSCRIPTION BY EPIGENETIC THERAPY IN ACUTE MYELOID LEUKEMIA CELL LINES M. Victor, A. Cras, P.Y. Boelle, B. Pollitis, H. Dombret, E. Raffoux, C. Chomienne (Inserm UMR S 940, Paris, France) |
| 0020 | SMALL MOLECULE XIAP INHIBITORS SENSITIZE CHILDHOOD ACUTE LEUKEMIA CELLS FOR DEATH RECEPTOR- OR CHEMOTHERAPY- INDUCED APOPTOSIS IN VITRO AND EXERT ANTILEUKEMIC ACTIVITY IN A NOD/SCID MOUSE MODEL IN VIVO S. Fulda, S. Löder, M. Fakler, K. Schneider, I. Jeremias, K.M. Debatin, S. Fulda (Ulm University, Ulm, Germany) |
| 0021 | CASPASE INHIBITION BLOCKS APOPTOSIS CAUSED BY MLL-AF4 DEPLETION IN T(4;11)-POSITIVE ALL CELL LINES, BUT CANNOT ABROGATE SUBSEQUENT NECROPTOSIS-LIKE CELL DEATH P. G. C. Garrido Castro, A. Gessner, J. Greil, O. Heidenreich (Newcastle University, Newcastle upon Tyne, United Kingdom) |
| 0022 | INDUCTION OF APOPTOSIS BY SHORT-TERM, HIGH-DOSE KINASE-INHIBITOR EXPOSURE IS A COMMON MECHANISM IN CELLS TRANSFORMED BY ONCOGENIC KINASES M.-C. Blum, F. Heidel, E. Ziesché, T. Kindler, T. Fischer, D.B. Lipka (Universitätsmedizin Mainz, Mainz, Germany) |
| 0023 | CHANGES OF NUCLEOLIN EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA E. Maloney, T. Ociepa, E. Kamienska, T. Urasinski, E. Urasinska (Pomeranian Medical University, Szczecin, Poland) |
| 0024 | THE EFFECT OF P16 ON GLUCOCORTICOID RESPONSES IN A B-CELL LYMPHOBLAST CELL LINE S.Y. Kim, E.S. Park, D.C. Jeong (Chungnam National University, Daejeon, South-Korea) |
| 0025 | PERIPHERAL BLOOD LYMPHOCYTE SUBSETS, TREG CELLS AND FOXP3 EXPRESSION IN ß-THALASSEMIA MAJOR AND ß-THALASSEMIA TRAIT PATIENTS E. Erdem, G. Bozdogan, G. Yanikkkaya Demirel, Y. Yildirmak (Sisli Etfal Research and Training Hospital, Istanbul, Turkey) |
GENOMICS AND PROTEOMICS & CYTOGENETICS AND MOLECULAR DIAGNOSTICS
| 0026 | PERSONALISED MEDICINE - THE USE OF PROTEOMICS BIOMARKERS TO PREDICT RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA |
|---|---|
| 0027 | DIFFERENT RESPONSES TO ADRIAMYCIN AND RADIATION ON RAJI CELLS: A COMPARATIVE MITOCHONDRIAL PROTEOMIC STUDY |
| 0028 | COMPARATIVE PROTEOMIC PROFILING OF SUBTYPE M1 AND M2 OF ACUTE MYELOID LEUKEMIA BY TWO-DIMENSIONAL ELECTROPHORESIS (2DE) AND MASS SPECTROMETRY |
| 0030 | SET-NUP214 EXPRESSION REQUIRES ALTERNATIVE SPLICING |
| 0031 | THE UNUSUAL MLL REARRANGEMENT IN ACUTE MYELOID LEUKEMIA I. Sarova, J. Brezinova, L. Lizcova, Z. Zemanova, O. Fuchs, A. Kostecka, D. Provaznikova, J. Filkukova, J. Maaloufova, K. Michalova (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) |
| 0032 | COMPLEX CHROMOSOMAL ABERRATIONS IN BONE MARROW CELLS OF 86 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) Z. Zemanova, K. Michalova, J. Brezinova, L. Lizcova, S. Izakova, D. Bystricka, I. Sarova, M. Siskova, R. Neuwirtova, O. Cerna, J. Cermak (General Teaching Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic) |
| 0033 | INTER-LABORATORY PERFORMANCE EVALUATION OF A NEW RQ-PCR ASSAY AIMED AT MEASURING RESPONSE TO TREATMENT IN CHRONIC PHASE CML PATIENTS F. Hermitte, J.R. Cook, J. Howell, K. Lyon, S. Turcan, V. Frayssinet, N. Maroc, R.R. Tubbs, A. Ferreira-Gonzalez (Ipsogen, Marseille, France) |
| 0034 | HIGH RESOLUTION MELTING ANALYSIS FOR THE RAPID DETECTION OF C-KIT MUTATIONS IN CORE BINDING FACTOR-ACUTE MYELOID LEUKEMIA O. Fuster, E. Barragan, P. Bolufer, J. Cervera, M.J. Larrayoz, A. Jimenez, J. Martínez, A. Valencia, F. Moscardó, M.A. Sanz (Hospital La Fe, Valencia, Spain) |
| 0035 | ANALYSIS OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) MRNA AS PREDICTOR OF DISEASE PROGRESSION AND RESPONSE TO THERAPY IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA H. ElAggan (Medical Research institute, Alexandria, Egypt) |
| 0036 | CONSTITUTIONAL RUNX1 DELETION IN NON-SYNDROMIC THROMBOCYTOPENIA; 21Q22 ITSN1 AS A CANDICATE GENE IN MENTAL RETARDATION A. Buijs (University Medical Center Utrecht, Utrecht, The Netherlands) |
| 0037 | DETECTION OF NUMERICAL CHROMOSOME ABERRATIONS IN RARE ACUTE MYELOID LEUKEMIA (AML) CELLS H. Minderman, J.C. Arcadi, A. Wierzbicki, E.S. Wang, S.N.J. Sait, A.W. Block, L. Liang, T. George, P.K. Wallace (Roswell Park Cancer Institute, USA) |
| 0038 | A RAPID, SENSITIVE AND SPECIFIC REAL-TIME POLYMERASE CHAIN REACTION ASSAY FOR QUANTIFICATION OF THE JAK2V617F ALLELE BURDEN B. Denys, H. El Housni, F. Nollet, B. Verhasselt, J. Philippé (Ghent University Hospital, Ghent, Belgium) |
| 0039 | MYELODYSPLASTIC SYNDROMES: USEFULNESS OF GENE EXPRESSION PROFILING FOR PROGNOSIS AND CELL MORPHOLOGY CLASSIFICATION M. Cabezón, L. Zamora, T. Berenguer, S. Marcé, N. Lloveras, B. Xicoy, D. Dominguez, J. Ribera, I. Portal, R. Guardia, D. Vela, J. Ayats, J. Buch, J.R. Grifols, M. Xandri, V. Moreno, J.M. Ribera, F. Millá, E. Feliu (Hospital Germans Trias i Pujol - ICO, Badalona, Spain) |
| 0040 | MOLECULAR CHARACTERISATION OF TRANSLOCATION (7;8) IN A CASE OF T-CELL LYMPHOBLASTIC LYMPHOMA J. Augustyniak, G.K. Przybylski, P. Grabarczyk, K. Dittmann, R. Siebert, S. Gesk, K. A_mus, G. Dölken, C.A. Schmidt (University of Greifswald, Greifswald, Germany) |
| 0041 | A BRANCHED DNA-BASED TECHNIQUE FOR DETECTION OF BCR-ABL GENE PRODUCTS M. Yakicier, T. Acun, S. Dizlek, A. Timuragaoglu (Bilkent University, Ankara, Turkey) |
| 0042 | GENOMIC IMBALANCES IN HCV-RELATED CRYOGLOBULINEMIAS C. Matteucci, G. Barba, D. Sansonno, F.A. Tucci, S. Romoli, D. Beacci, M.F. Martelli, F. Dammacco, C. Mecucci (University of Perugia, Perugia, Italy) |
| 0043 | FRAGMENT LENGTH ANALYSIS SCREENING FOR CEBPA MUTATIONS DETECTION IN ACUTE MYELOID LEUKEMIA O. Fuster, E. Barragan, P. Bolufer, J. Cervera, E. Such, P. Montesinos, M.A. Sanz (Hospital La Fe, Valencia, Spain) |
| 0044 | MUTATIONS IN THE IRF ASSOCIATION DOMAIN OF THE TRANSCRIPTION FACTOR GENE ICSBP MAY BE ASSOCIATED WITH LEUKEMOGENESIS IN SHWACHMAN-DIAMOND SYNDROM N. Otto, C. Zeidler, K. Welte, B. Schlegelberger, D. Steinemann (MHH, Hannover, Germany) |
| 0045 | A NEW RELIABLE FISH METHOD FOR IDENTIFYING MULTIPLE SPECIFIC CYTOGENETIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA A. Valencia, J. Cervera, E. Such, E. Gamero, E. Barragan, O. Fuster, P. Bolufer, F. Moscardo, M.A. Sanz (Hospital Universitario La Fe, Valencia, Spain) |
CYTOGENETICS AND MOLECULAR DIAGNOSTICS
| 0046 | ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA GENE MUTATIONS AND NORMAL KARYOTYPE REPRESENTS A DISTINCT GENETIC ENTITY ASSOCIATED WITH A FAVORABLE CLINICAL OUTCOME |
|---|---|
| 0047 | MENINGIOMA GENE (MN1) EXPRESSION IS A SENSITIVE MARKER FOR MINIMAL RESIDUAL DISEASE DETECTION IN ACUTE MYELOID LEUKAEMIA |
| 0048 | MEASUREMENT OF MICRORNA EXPRESSION LEVELS BY QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION IS A USEFUL TOOL TO PREDICT OUTCOME IN PATIENTS WITH B CELL CHRONIC LYMPHOCYTIC LEUKAEMIA |
| 0049 | STANDARDIZATION OF MINIMAL RESIDUAL DISEASE FOR MINOR-BCR-ABL TRANSCRIPTS IN PH+ALL: A EUROPEAN APPROACH OF THE EWALL AND ESG-MRD-ALL CONSORTIA |
| 0050 | JAK2 V617 ALLELE BURDEN AND THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA E. Kalagiakou, I. Evmorfiadis, M. Hatzouli, E. Manioudaki, M. Kotsopoulou, S. Malegkou, K. Vallianatou, I.-D. Triantafyllopoulou, E. Samaridis, L. Dadiotis, Ch. Mitsouli, C. Belessi, N. Laoutaris (Nikea General Hospital, Athens, Greece |
| 0051 | MONOCLONALITY TESTING USING PYROSEQUENCING D.R. Robert, P. Makrythanasis, S. Mach-Pasqual, P. Beris, S. Antonarakis, S. Deutsch, T. Matthes (University Hospital Geneva, Geneva, Switzerland) |
| 0052 | COOPERATING MUTATIONS OF RECEPTOR TYROSINE KINASES/ JAK2/RAS SIGNALING PATHWAYS IN DE NOVO AML WITH MLL TRANSLOCATIONS AT DIAGNOSIS AND RELAPSE L.-Y. Shih, D.-C. Liang, C.-F. Huang, J.-F. Fu, T.-L. Lin, M.-C. Kuo, C.-L. Lai, T.-H. Lin (Chang Gung Memorial Hospital, Taipei, Taiwan) |
| 0053 | PROGNOSTIC SIGNIFICANCE OF TELOMERE LENGTH, MOLECULAR CYTOGENETIC FINDINGS AND IMMUNOPHENOTYPIC FEATURES IN PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA J. Brezinova, S. Vcelikova, A. Berkova, Z. Zemanova, I. Izakova, I. Sarova, H. Cechova, J. Tajtlova, L. Grosova, L. Lizcova, E. Malinova, M. Zemanova, E. Cmunt, J. Karban, J. Schwarz, K. Michalova (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) |
| 0054 | B-CELL LYMPHOPROLIFERATIVE DISORDERS WITH T(1;14)(Q13;Q32) OR T(4;18)(Q32;Q21) SHOW VARIATIONS IN THE PATTERN OF ADDITIONAL CYTOGENETIC ABERRATIONS, GENE EXPRESSION PROFILE AND ANTIGEN EXPRESSION F. Dicker, L. Reindl, S. Schnittger, T. Haferlach, W. Kern, C. Haferlach (MLL Munich Leukemia Laboratory, Munich, Germany) |
| 0055 | ASSOCIATION OF INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (IP-FISH) RESPONSE CRITERIA WITH CONVENTIONAL METAPHASE CYTOGENETICS IN CML PATIENTS ON THERAPY T. Schenk, M.C. Müller, A. Fabarius, P. Erben, H. Daikeler, T. Ernst, A. Hochhaus, C. Haferlach (Universitaetsmedizin Mannheim, Mannheim, Germany) |
| 0056 | FREQUENT MONITORING OF WILMS' TUMOR GENE (WT1) EXPRESSION LEVELS IN PERIPHERAL BLOOD FOR EARLY DIAGNOSIS OF ACUTE LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION H. Tamaki, R. Kato, K. Ikegame, T. Fujioka, Y. Taniguchi, S. Yoshihara, K. Kaida, T. Inoue, H. Ogawa (Hyogo College of Medicine, Nishinomiya City, Japan) |
| 0057 | DNA METHYLATION PROFILES OF DIFFERENT LYMPHOID MALIGNANCIES C. Stanganelli, C. Chena, I. Slavutsky (Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina) |
| 0058 | TET2 DELETION IS A COMMON DENOMINATOR IN HAEMATOLOGICAL PATHOLOGIES WITH 4Q24 REARRANGEMENTS R. La Starza, E. Varasano, B. Crescenzi, G. Barba, N. Testoni, V. Gianfelici, V. Pierini, C. Baldazzi, V. Nofrini, A Pierini, T Zei, M.F. Martelli, C. Mecucci (University of Perugia, Perugia, Italy) |
| 0059 | COMBINATION OF FT-CGH AND LM-PCR ALLOWS MOLECULAR CHARACTERIZATION OF CHROMOSOMAL ALTERATIONS IN T-ALL CASES K. Dittmann, G.K. Przybylski, P. Grabarczyk, S. Gesk, G. Dölken, R. Siebert, C.A. Schmidt (University of Greifswald, Greifswald, Germany) |
| 0060 | AN ACCURATE MLPA SCREENING METHOD FOR MLL-PTD DETECTS A LOW FREQUENCY OF MLL-PTD IN PEDIATRIC ACUTE MYELOID LEUKEMIA B.V. Balgobind, I.H.I.M. Hollink, D. Reinhardt, E. van Wering, S.S.N. de Graaf, A. Baruchel, J. Stary, H.B. Beverloo, G.E. de Greef, R. Pieters, C.M. Zwaan, M.M. van den Heuvel-Eibrink (Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands) |
| 0061 | FLOW CYTOMETRIC DETECTION OF NG2 ANTIGEN FOR EARLY IDENTIFICATION OF CHILDHOOD ACUTE LEUKEMIAS WITH MLL GENE REARRANGEMENTS L. Sedek, J. Bulsa, A. Gaworczyk, I. Malinowska, M. Niedzwiecki, K. Derwich, J. Trelinska, K. Muszynska-Roslan, I. Olejnik, A. Mizia-Malarz, W. Balwierz, W. Badowska, I. Ruranska, B. Mazur, M. Matysiak, J.R. Kowalczyk, T. Szczepanski (Medical University of Silesia, Zabrze, Poland) |
| 0062 | DELETION OF 14Q INVOLVING IGH GENE IN PATIENTS WITH MULTIPLE MYELOMA J. Balcarkova, T. Pika, H. Urbankova, M. Holzerova, V. Scudla, J. Bacovky, K. Indrak, M. Jarosova (University Hospital Olomouc, Olomouc, Czech Republic) |
| 0063 | A NOVEL CHROMOSOMAL TRANSLOCATION T(1;14)(Q24.1;Q32) INVOLVING IGH IN CHILDHOOD B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA (BCP-ALL) E. Tassano, M. Acquila, E. Tavella, C. Rosanda, C. Micalizzi, C. Panarello, C. Morerio (Istituto Giannina Gaslini, Genoa, Italy) |
| 0064 | K-RAS MUTATIONS IN CYTOGENETICALLY NORMAL AML PATIENTS A. Morgan, J. Krauter, F. Onono, T. Bunke, F. Damm, G. Göhring, B. Schegelberger, A. Ganser, C.W.M. Reuter (Hannover Medical School, Hannover, Germany) |
CELLULAR IMMUNOTHERAPY AND VACCINATION
| 0065 | TARGETING LEWIS Y-EXPRESSING MULTIPLE MYELOMA AND ACUTE MYELOID LEUKEMIA WITH GENE-MODIFIED T CELLS DEMONSTRATING MEMORY PHENOTYPE |
|---|---|
| 0066 | PEPTIDE VACCINATION ELICITS LEUKEMIA-ASSOCIATED ANTIGENSPECIFIC CYTOTOXIC CD8+ T-CELL RESPONSES WITH POTENTIAL CLINICAL RELEVANCE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA |
| 0067 | EPIGENETIC MANIPULATION OF TUMOUR ANTIGEN EXPRESSION: A STRATEGY FOR SELECTIVELY UP-REGULATING THE GRAFTVERSUS LEUKAEMIA RESPONSE IN PATIENTS ALLOGRAFTED FOR HAEMATOLOGICAL MALIGNANCIES |
| 0068 | HIGH-DOSE RHAMM-R3 PEPTIDE VACCINATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), MYELODYSPLASTIC SYNDROME (MDS) AND MULTIPLE MYELOMA (MM) |
| 0069 | CLINICAL RESPONSES IN ALLOGRAFTED ACUTE LEUKEMIA PATIENTS WITH RESISTANT DISEASE USING A COMBINED CHEMO-IMMUNOTHERAPEUTIC TREATMENT STRATEGY G.F. Torelli, W. Barberi, R. Maggio, M.S. De Propris, N. Peragine, A.P. Iori, F. Natalino, A. Guarini, R. Foà (Sapienza University of Rome, Rome, Italy) |
| 0070 | RNA-MODIFIED DENDRITIC CELLS AS THERAPEUTIC VACCINES N. Berneman, A. Van Driessche, A. Van de Velde, A. Schroyens, P. Gadisseur, I. Vrelust, G. Nijs, B. Stein, K. Vermeulen, K. Pieters, N. Cools, R. Van Gulck, G. Vanham, F. Van Tendeloo (University of Antwerp, Vaccine and Infectious Disease Institute, Edegem, Belgium) |
| 0071 | IN VITRO GENERATION OF BOTH CONVENTIONAL AND UNCONVENTIONAL MATURE TCRAB CELLS FROM HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS S. Van Coppernolle, G. Verstichel, I. Velghe, J. Plum, B. Vandekerckhove, C.C. Kerre (UZ Gent, Ghent, Belgium) |
| 0072 | IMMUNOSTIMULATORY LEUKEMIC DENDRITIC CELLS CAN EFFICIENTLY EXPAND LEUKAEMIA-REACTIVE T CELLS FROM HSCT DONORS M. Casucci, S.K. Perna, A. Bondanza, Z. Magnani, M. Bernardi, A. Crotta, C. Tresoldi, K. Fleischhauer, F. Caligaris-Cappio, F. Ciceri, C. Bordignon, A. Cignetti, C. Bonini (San Raffaele Scientific Institute, Milan, Italy) |
| 0073 | IN VITRO ACTIVATION OF MYELOMA-SPECIFIC CYTOTOXIC T CELLS BY MUC1 PULSED DENDRITIC CELLS F. Kryukov, L. Zahradová, D. Ocadlíková, L. Kovárová, E. Matejková, R. Hájek, J. Michálek (Masaryk University, Brno, Czech Republic) |
| 0074 | CYTOKINE INDUCED KILLER CELLS : IN VITRO DIFFERENTIATED T CELLS WITH ANTI-TUMORAL ACTIVITY A. Pievani, G. Borleri, M. Franceschetti, L. Vago, K. Fleischhauer, J. Golay, M. Introna (Laboratory of Cellular Therapy “G.Lanzani”, Bergamo, Italy) |
ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL
| 0075 | A NOVEL DASATINIB-SENSITIVE RCSD1-ABL1 FUSION TRANSCRIPT IN CHEMOTHERAPY-REFRACTORY ADULT PRE-B LYMPHOBLASTIC LEUKEMIA WITH T(;9)(Q24;Q34) |
|---|---|
| 0076 | LONG-TERM FOLLOW-UP OF HIV-INFECTED ADULT PATIENTS WITH BURKITT'S LYMPHOMA OR LEUKEMIA TREATED WITH INTENSIVE SPECIFIC CHEMOTHERAPY AND RITUXIMAB |
| 0077 | THE LONG-TERM OUTCOME OF ELDERLY PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN THE IMATINIB ERA |
| 0078 | THE HUMORAL IMMUNE RESPONSE DURING THE L-ASPARAGINASE THERAPY - THREE CLASSES OF ANTIBODIES |
| 0079 | LIPOSOMAL CYTARABINE FOR THE PROPHYLAXIS OF CENTRAL NERVOUS SYSTEM RELAPSE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA. INTERIM ANALYSIS OF THE PALG 5-2007 ALL STUDY J. Piszcz, B. Piatkowska-Jakubas, S. Giebel, A. Grzywacz, M. Adamczyk- Cioch, L. Bolkun, M. Krawczyk-Kulis, A. Holowiecka, J. Holowiecki (Bialystok Medical Academy, Bialystok, Poland) |
| 0080 | QUALITATIVE AND QUANTITATIVE CONCORDANCE IN MRD DATA, ASSESSED BY FLOW CYTOMETRY AND RT-PCR OF FUSION GENE TRANSCRIPTS IN INFANTS WITH MLL-REARRANGED ALL A. Popov, G. Tsaur, A. Ivanova, Y. Yakovleva, T. Verzhbitskaya, T. Riger, E. Shorikov, L. Saveliev, L. Fechina (Ural State Medical Academy, Ekaterinburg, Russian Federation) |
| 0081 | OUTCOME FOR ADOLESCENT AND YOUNG ADULTS UP TO AGE 35 YEARS (AYA) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED ON THE PEDIATRIC PROTOCOLS OF MOSCOW-BERLIN 91 AND 2002 S.V. Semochkin, S.S. Kulikova, L.A. Antipova, V.V. Lunin, A.G. Rumiantsev (Federal Scientific Clinical Center for Pediatric Hematology, Oncology and Immuno, Moscow, Russian Federation) |
| 0082 | HUMORAL IMMUNITY TO DIPHTHERIA, TETANUS, MEASLES, AND HAEMOPHILUS INFLUENZAE TYPE B IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND RE-VACCINATION RESPONSES E. Zengin, N. Sarper (Kocaeli University, Kocaeli, Turkey) |
| 0083 | PROGNOSTIC SIGNIFICANCE OF ULTRASOUND-DETECTED BOWEL WALL THICKENING IN NEUTROPENIC ENTEROCOLITIS T. Hassan, M. Atfy, M. El Tohamy (Zagazig University, Zagagzig, Egypt) |
HODGKIN LYMPHOMA
| 0084 | EARLY AND LATE RESPONSE ASSESSMENT WITH FDG-PET AFTER BEACOPP-BASED CHEMOTHERAPY IN ADVANCEDSTAGE HODGKIN LYMPHOMA PATIENTS HAS A HIGH NEGATIVE PREDICTIVE VALUE |
|---|---|
| 0085 | VEBEP REGIMEN AND HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN PATIENTS (PTS) WITH HD AND HIV INFECTION (HD-HIV): FINAL RESULTS OF THE ITALIAN COOPERATIVE GROUP ON AIDS AND TUMORS (GICAT) STUDY |
| 0086 | 18FDG-PET-NEGATIVE COMPLETE REMISSION PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION PREDICTS FOR SUPERIOR EVENT FREE SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA |
| 0087 | EARLY FDG-PET SCAN CONFIRMS ITS PROGNOSTIC IMPACT ALSO IN LOCALIZED STAGE, ABVD TREATED HODGKIN LYMPHOMA PATIENTS |
| 0088 | PHASE II STUDY OF ORAL PANOBINOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) AFTER HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) A. Younes, A. Sureda, D. Ben-Yehuda, T.C. Ong, D. Tan, A. Engert, C. Le Corre, J. Gallagher, S. Hirawat, M. Prince (M. D. Anderson Cancer Center, Houston, USA) |
| 0089 | QUALITY OF LIFE AND FERTILITY IN HODGKIN DISEASE (HD) PATIENTS TREATED WITH ESCALATED BEACOPP W. Jurczak, D. Krochmalczyk, W. Pabian, P. Chrapczynski, A. Cwierz, A. Giza, M. Sobocinski, D. Zimowska-Curylo, A.B. Skotnicki (Dpt of Haematology, Kraków, Poland) |
| 0090 | TANDEM AUTOLOGOUS/REDUCED-INTENSITY ALLOGRAFT FOR RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA: EARLY ALLOTRANSPLANT AFTER INTENSIVE CYTOREDUCTION MAY MAXIMIZE GRAFT VS LYMPHOMA EFFECT? E. Todisco, A.G. Congiu, L. Castagna, S.T. Nati, A. Santoro, A.M. Carella (Istituto Clinico HumanitasI, Rozzano Milan, Italy) |
| 0091 | QUALITY OF LIFE IN A 2-YEAR FOLLOW-UP: SIGNS OF PNP PREDICTING FATIGUE IN SURVIVORS TREATED IN THE HD10-12 TRIALS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) T. Halbsguth, H. Mueller, H.-H. Flechtner, C. Brillant, K. Behringer, Th. Schober, H. Nisters-Backes, A. Engert, P. Borchmann (University of Cologne, Cologne, Germany) |
| 0092 | EXPRESSION AND EPIGENETIC ANALYSIS OF KEY B-LINEAGE TRANSCRIPTIONAL PROGRAMMES IN HODGKIN / REED-STERNBERG CELLS G.P. Collins, J.C. Paterson, L. Campbell, D.Y. Mason, T. Enver, T. Marafioti (John Radcliffe Hospital, Oxford, United Kingdom) |
| 0093 | PLASMA LEVELS OF CIRCULATING CELL-FREE DNA AND OF CYTOKINES AS POTENTIAL BIOMARKERS IN HODGKIN LYMPHOMA S. Hohaus, G. Massini, M. Giachelia, B. Vannata, M. Criscuolo, M.C. Tisi, M. Martini, F. D'Alò, L.M. Larocca, M.T. Voso, G. Leone (Università Cattolica S. Cuore, Rome, Italy) |
| 0094 | THE INFLUENCE OF POLYMORPHISMS OF GLUTATHIONE S-TRANSFERASE MU (GSTM1), THETA (GSTT1) AND PI (GSTP1) GENES IN THE OUTCOME OF HODGKIN'S LYMPHOMA I. Lorand-Metze, G.J. Lourenço, M.T. Delamain, E.C.M. Miranda, R.E. Kameo, C.S.P. Lima (State University of Campinas, Campinas, Brazil) |
| 0095 | ANTHRACYCLINE CARDIOTOXITY OCCURS EARLY DURING THERAPY IN CHILDREN WITH HODGKIN'S DISEASE A. Tantawy, O.A. Elmasry, D.N. Toaima, A.M. El Shahat (Faculty of Medicine, Ain Shams University, Cairo, Egypt) |
| 0096 | COMPLETE RESPONSE (CR) TO IGEV (IFOSFAMIDE, GEMCITABINE AND VINORELBINE) AND OUTCOME IN RELAPSED/ REFRACTORY HODGKIN'S LYMPHOMA (HL) PATIENTS A. Anastasia, R. Mazza, L. Giordano, M. Balzarotti, M. Magagnoli, L. Castagna, M. Spina, U. Tirelli, A. Santoro (Istituto Clinico Humanitas, Rozzano, Italy) |
| 0097 | THE PROGNOSTIC SIGNIFICANCE OF PET SCAN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) TREATED WITH HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDT/ASCT) M. Moschogiannis, T.P. Vassilakopoulos, G.A. Pangalis, P. Tsirkinidis, V. Pappi, O. Tsopra, S. Sachanas, Z. Galanis, M. Angelopoulos, X. Yiakoumis, C. Kalpadakis, M.P. Siakantaris, K. Konstantopoulos, M.-C. Kyrtsonis, P. Panayiotidis, M.K. Angelopoulou (National and Kapodistrian University of Athens, Athens, Greece) |
| 0098 | LOW INCIDENCE OF PREMATURE OVARIAN FAILURE (POF) IN FEMALE PATIENTS TREATED FOR HODGKIN LYMPHOMA DURING PREPUBERTAL OR POSTPUBERTAL PHASE S. Falorio, G. La Barba, F. Fioritoni, G. Fioritoni, F. Angrilli (Civic Hospital, Pescara, Italy) |
| 0099 | COMPARATIVE STUDY OF TWO MOPP-DERIVED CHEMOTHERAPEUTIC PROTOCOLS FOR MANAGEMENT OF PEDIATRIC HODGKIN'S DISEASE: SINGLE CENTER 5-YEARS EXPERIENCE Y. Al-Tonbary, M. Abul-Kheir, A. EL-Ashry, E.E. Salama, M. Sedky, E. Fouda (Mansoura University Children's Hospital, Mansoura, Egypt) |
| 0100 | INTERLEUKIN-12 GERMLINE POLYMORPHISM AND OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA: A PROSPECTIVE STUDY OF THE GROUPE D'ETUDE DES LYMPHOMES DE L'ADULTE H. Ghesquieres, O. Casasnovas, M. Fournier, D. Cox, P. Brice, F. Morschhauser, A. Verney, C. Sebban, V. Ribrag, C. Haioun, P. Feugier, H. Tilly, C. Ferme, G. Salles (Centre Leon Berard, Lyon, France) |
BLEEDING DISORDERS (CONGENITAL AND ACQUIRED)
| 0101 | RECURRENT MUTATIONS IDENTIFIED ON LMAN1 AND COAGULATION FACTORS VII, X, XIII GENES |
|---|---|
| 0102 | MANAGEMENT OF ACUTE HAEMARTHROSIS IN HAEMOPHILIA: A EUROPEAN SURVEY |
| 0103 | CIRCULATING (CEC) VERSUS PROGENITOR (CEP) ENDOTHELIAL CELLS ARE ABNORMAL IN PATIENTS WITH DIFFERENT TYPES OF VON WILLEBRAND DISEASE AND CORRELATE WITH MARKERS OF ANGIOGENESIS: A COHORT STUDY OF 74 CASES |
| 0104 | THE HEMOSTATIC POTENTIAL OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) CELLS BY THE CALIBRATED AUTOMATED THROMBOGRAM ASSAY (CAT): MODULATION BY ARSENIC TRIOXIDE (ATO) AND ALL-TRANS RETINOIC ACID (ATRA) |
| 0105 | SINGLE CENTRE EXPERIENCE OF DESMOPRESSIN RESPONSE IN CHILDREN WITH MILD FVIII DEFICIENCY, VON WILLEBRANDS DISEASE AND PLATELET FUNCTION DEFECTS A. Breen, M. Kavanagh, I. Kelly, B. Nolan, I. Regan, P. Smith, C. McMahon (Our Lady's Children's Hospital, Dublin, Ireland) |
| 0106 | GENZ-11263, AN INVESTIGATIONAL ORAL THERAPY FOR GAUCHER DISEASE TYPE 1: PHASE 2 CLINICAL TRIAL RESULTS AFTER ONE YEAR OF TREATMENT E. Lukina, N. Watman, E. Arreguin, M. Banikazemi, G. Pastores, M. Iastrebner, M. Dragosky, H. Rosenbaum, A. Zimran, M. Kaper, S.E. Smith, A.C. Puga, J. Peterschmitt (Russian Academy of Medical Sciences, Moscow, Russian Federation) |
| 0107 | GAUCHER DISEASE DIAGNOSTIC AND DISEASE MANAGEMENT ALGORITHMS: A GUIDE FOR HEMATOLOGISTS M.D. Cappellini, P. K. Mistry, E. Lukina, H. Özsan, S.M. Pascual, H. Rosenbaum, M.H. Solano, Z. Spigelman, J. Villarrubia, N.P. Watman, G. Massenkeil (University of Milan, Milan, Italy) |
| 0108 | THE SEQUENTIAL COMBINED BYPASSING THERAPY (SCBT) IS EFFECTIVE AND SAFE IN THE TREATMENT OF UNRESPONSIVE BLEEDS IN HAEMOPHILIA PATIENTS WITH INHIBITORS A. Gringeri, K. Fischer, A. Karafoulidou, M.F. López-Fernández (University of Milan, Milan, Italy) |
| 0109 | PREVALENCE OF VWD IN IRAN M. Lak, H. Mansouritorghabeh (Tehran University of Medical Sciences, Tehran, Iran) |
| 0110 | COMPARATIVE STUDY OF CLINICAL, X-RAY AND MRI SCORES IN THE FOLLOW-UP OF HAEMOPHILIC ARTHROPATHY H. Pergantou, H. Platokouki, A. Papadopoulos, G. Matsinos, P. Xafaki, S. Aronis (Agia Sophia Children's Hospital, Athens, Greece) |
| 0111 | MUTATION SPECTRUM OF SEVERE VON WILLEBRAND DISEASE TYPE 3 IN INDIA F. Ahmad, R. Schneppenheim, F. Oyen, T. Obser, U. Budde, M. Kannan, R. Saxena (All India Institute of Meical Sciences, New Delhi, India) |
| 0112 | INCIDENCE OF LUPUS ANTICOAGULANT IN HEMOPHILIA PATIENTS V. Krasivska, O. Stasyshyn, V. Loginsky (State institution “Institute of Blood Pathology and Transfusion Medicine of AMS, Lviv, Ukraine) |
| 0113 | INDIVIDUALISED ORAL VITAMIN K FOR REVERSAL OF WARFARIN EXCESSIVE ANTICOAGULATION M. Briz, K. Talks, J. Hanley, P. Kesteven, P. Avery, A. Daly, F. Kamali (Hospital Sierrallana, Torrelavega, Spain) |
| 0114 | NOVEL ASSOCIATION BETWEEN ACQUIRED TYPE 2 VON WILLEBRAND DISEASE AND GLYCOGEN STORAGE DISEASE IA (GSD IA): A REPORT OF 3 AFFECTED SIBLINGS Y.S. Sorour, M.J. Sharrard, A. Vora, G.T. Gillett, J.H. Payne (Haematology Department, Sheffield Children’s Hospital NHS Foundation Trust, Sheffield, United Kingdom) |
| 0115 | BONE STATUS OF CHILDREN WITH HEMOPHILIA A ASSESSED WITH DUAL ENERGY X-RAY ABSORPTIOMETRY (DXA) AND QUANTITATIVE ULTRASONOGRAPHY (QUS): COMPARISONS AND CORRELATIONS M. Economou, A. Christoforides, E. Papadopoulou, N. Gompakis, M. Athanassiou-Metaxa (Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece) |
| 0116 | FUNCTIONAL CHARACTERIZATION OF FIBRINOGEN POZNAN: A PREMATURE TRUNCATING MUTATION IN FGG ASSOCIATED WITH HYPOFIBRINOGENEMIA AND MILD BLEEDING TENDENCY M. Zawilska, A. Undas, L. Malendowicz-Portala, P. de Moerloose, R. Fish, M. Neerman-Arbez (J.Strus Hospital, Poznan, Poland) |
| 0117 | DIFFERENT REGIMENS OF PROPHYLAXIS TREATMENT IN YOUNG SEVERE HEMOPHILIA A PATIENTS: COMPARISONS ON EFFICACY, FVIII CONSUMPTION AND THERAPY COMPLIANCE C. Santoro, F. Biondo, A.P. Leporace, R. Foà, M.G. Mazzucconi (Hematology, Rome, Italy) |
| 0118 | PHYSICAL ACTIVITY AS PREVENTION OF OSTEOPOROSIS IN PATIENTS WITH SEVERE HAEMOPHILIA ON LONG TERM PROPHYLAXIS M. Khawaji, J.E. Berntorp (Malmö University Hospital, Malmö, Sweden) |
| 0119 | AN INVESTIGATION INTO THE EFFECT OF STORAGE TIME ON THE STABILITY OF SAMPLES FOR INR DETERMINATION AND THE RELIABILITY OF RESULTS THROUGH DELAYED INR DETERMINATION C. Woods, G. McLoughlin, J. Bowers (South Eastern Trust, Belfast,United Kingdom) |
| 0120 | PREOPERATIVE EVALUATION OF PLATELET FUNCTION WITH THE PFA-100 IN ORTHOPEDIC PATIENTS RECEIVING ASPIRIN AND/OR CLOPIDOGREL N. Tragomalos, T. Assimakopoulou, M. Stamouli, A. Giotsidou, I. Anagnosti, P. Lianidou (KAT Hospital, Kifissia, Greece) |
| 0121 | ACQUIRED HAEMOPHILIA; A COHORT OF 26 PATIENTS DIAGNOSED AND TREATED IN THE SOUTH EAST OF ENGLAND BETWEEN JAN 1996-2009 B. Chowdhury (St Thomas' Hospital, London, United Kingdom) |
| 0122 | COAGULATION SCREENING IN AN IRISH TEACHING HOSPITAL J. McHugh, C. Holt, D. O'Keeffe (Mid Western Regional Hospital, Limerick, Ireland) |
QUALITY OF LIFE, PALLIATIVE CARE AND ETHICS
| 0123 | VALIDATION OF THE BRAZILIAN PORTUGUESE VERSION OF THE MEDICAL OUTCOMES STUDY - SOCIAL SUPPORT SURVEY IN HODGKIN LYMPHOMA SURVIVORS |
|---|---|
| 0123a | QUALITY OF LIFE IN PATIENTS WITH VWD |
| 0124 | PAIN RATE AND SOCIAL CIRCUMSTANCES RATHER THAN CUMULATIVE ORGAN DAMAGE DETERMINE THE QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE |
| 0125 | HEALTH-RELATED QUALITY OF LIFE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTRE PROSPECTIVE STUDY IN THE CZECH REPUBLIC (FINAL RESULTS) |
| 0126 | INFLUENCE OF ANEMIA ON QOL, CLINICAL SYMPTOMS AND COGNITIVE FUNCTIONS IN NEWLY DIAGNOSED (NOT TREATED) HEMATOLOGIC PATIENTS D. Petranovic, R. Dobrila Dintinjana, A. Duletic Nacinovic, T. Valkovic, I. Roncevic Grzeta, K. Ruzic, S. Janovic, R. Rakun, Z. Striskovic, M. Petkovic, I. Lovasic, G. Golcic (Clinical Hospital Center Rijeka, Riijeka, Croatia) |
| 0127 | HOME CARE FOR UNFIT ELDERLY PATIENTS WITH MYELODISPLASTIC SYNDROMES: AN ITALIAN SINGLE-CENTER EXPERIENCE P. Alfieri, L. Ferrara, G. Leonardi, M. Luppi, R. Marasca, G. Torelli, E. Favale (AIL Hematology Home Care Service, Modena, Italy) |
| 0128 | PAIN MANAGEMENT OF BORTEZOMIB-INDUCED NEUROPATHY WITH ORAL CONTROLLED-RELEASE OXYCODONE C. Cartoni, G.A. Brunetti, P. Niscola, P.L. Alfieri, G.M. Delia, R. Foà (Hematology, University of Rome, Rome, Italy) |
| 0129 | HOW HAEMOPHILIA IMPACTS THE QUALITY OF LIFE OF ELDERLY PATIENTS S. von Mackensen, A. Gringeri, S.M. Siboni, M. Ferretti, F. Tradati, M. Franchini, A. Tagliaferri, P.M. Mannucci (University Hamburg, Hamburg, Germany) |
| 0130 | SINGLE DOSE PALONOSETRON IN PREVENTING CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH AGGRESSIVE NON HODGKIN'S LYMPHOMAS (NHL) WHO UNDERWENT MODERATELY EMETOGENIC CHEMOTHERAPY (MEC) N. Di Renzo, A. Montanini, A. Dondi, S. Muci, E. Iannitto, M.R. De Paolis, C. Plati, C. Stelitano, C. Patti, A. Olivieri, E. Liardo, G. Buda, R. Cantaffa, M. Federico (Vito Fazzi - Hospital, Lecce, Italy) |
| 0131 | PHYSICIANS AND PATIENTS PERCEPTION OF A PROBLEM AS ETHICALLY RELEVANT IN ONCOHEMATOLOGY: ONLY A QUESTION OF PERSPECTIVE? G. Giordano, D. Sacchini, S. Piano, G. Farina, I . Carrasco de Paula, S. Storti (Research Center “J.Paul II” Catholic University Campobasso, Campobasso, Italy) |
| 0132 | COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT IN EUROPE M. Monreal, L. Ryttberg, A. Diamantopoulos, M. Lees, C. Negrini (Hospital Universitari Germans Trias i Pujol of Badalona, Barcelona, Spain) |
| 0133 | ANALYSIS OF COSTS ASSOCIATED WITH REMOBILIZATION OF HEMATOPOIETIC STEM CELLS (HSC) USING CHEMOTHERAPY, IN PATIENTS WITH MULTIPLE MYELOMA FAILING ADEQUATE HSC COLLECTION FOR AUTOLOGOUS STEM CELL TRANSPLANTATION WITH G-CSF ALONE C. Hosing, V.R. Smith, B. Rhodes, R. Richmond, K.H. Walters, M.H. Qazilbash, J.D. McMannis, R. Champlin, S. Giralt, U.R. Popat (M. D. Anderson Cancer Center, Houston, USA) |
| 0134 | DEVOLOPMENT OF A TIME-DRIVEN ACTIVITY-BASED COSTING MODEL FOR ASSESSING THE SOCIETAL ACQUISITION COST OF ERYTHROCYTE CONCENTRATES IN EUROPE D. Szucs, J. Bauwens, J. Alfonso, N. Holtuis, J. Von Knorring, J. Demey (University Zurich, Zurich, Switzerland) |
| 0135 | HEALTH ECONOMIC IMPACT OF INTRAVENOUS IRON SUPPLEMENTATION IN ANEMIA TREATMENT WITH ERYTHROPOIESIS-STIMULATING AGENTS D. Szucs, R. Blank, M. Schwenkglenks (University Zurich, Zurich, Switzerland) |
STEM CELL TRANSPLANTATION – GVHD, GRAFT REJECTION, INFECTION
| 0136 | PREVALENCE OF HUMAN HERPES VIRUS 6 CHROMOSOMAL INTEGRATION (CIHHV-6) IN ITALIAN ALLOGENEIC STEM CELL AND SOLID ORGAN TRANSPLANTATION PATIENTS |
|---|---|
| 0137 | GENETIC VARIATIONS IN HEPARANASE GENE (HPSE) ARE ASSOCIATED WITH INCREASED RISK OF GRAFT VS. HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) |
| 0138 | IMMUNE RECONSTITUTION AND RISK OF CYTOMEGALOVIRUS INFECTION IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IMPLICATIONS FOR PREEMPTIVE AND PROPHYLACTIC STRATEGIES |
| 0139 | EXPANSION AND SUPPRESSIVE FUNCTION OF UMBILICAL CORD BLOOD REGULATORY T CELLS |
| 0140 | THE MODULATORY PROPERTIES OF REGULATORY T CELLS IN THE PERIPHERAL BLOOD OF PATIENTS WHO HAVE UNDERGONE AN ALLOGENEIC STEM CELL TRANSPLANT CORRELATE WITH THE PRESENCE OF GRAFT-VERSUS-HOST DISEASE G.F. Torelli, R. Maggio, N. Peragine, M.S. De Propris, B. Lucarelli, M.G. Mascolo, A.P. Iori, V. Valle, E. Iannella, A. Guarini, R. Foà (Sapienza University of Rome, Rome, Italy) |
| 0141 | DIVERSITY AND DIFFERENTIAL INVOLVEMENT OF HLA CLASS I AND II RESTRICTED MINOR HISTOCOMPATIBILITY ANTIGENS IN GRAFT-VERSUS-LEUKEMIA REACTIVITY M. Griffioen, A.N. Stumpf, M.W. Honders, E.D. van der Meijden, S.A.P. van Luxemburg-Heijs, C.A.M. van Bergen, R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center, Leiden, The Netherlands) |
| 0142 | CYCLOSPORINE, METHOTREXATE AND METHYLPREDNISOLONE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN CHILDREN WITH HEMOGLOBINOPATHIES: A PROSPECTIVE STUDY J. Gaziev, G. Lucarelli, A. Santucci, C. Gallucci, P. Sodani, P. Polchi, A. Isgrò,M. Marziali, K. Paciaroni, M.D. Simone, A. Roveda, A. Montuoro, C. Alfieri,G. De Angelis (Mediterranean Institute of Hematology, Rome, Italy) |
| 0143 | ALLOANTIGEN-SPECIFIC DE NOVO INDUCED FOXP3+ REGULATORY T CELLS FAIL TO PREVENT GVHD DUE TO IN VIVO INSTABILITY C. Koenecke, N. Czeloth, A. Bubke, S. Schmitz, A. Kissenpfennig, B. Malissen, J. Huehn, A. Ganser, R. Förster, I. Prinz (Hannover Medical School, Hannover, Germany) |
| 0144 | RECOVERY OF SPECIFIC CMV CD8+ T LYMPHOCYTES AND T REG AFTER ALLOGENEIC PERIPHERAL STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE D. Pastore, M. Delia, P. Carluccio, A. Mestice, M. Leo, A. Ricco, F. Gaudio, A.M. Giordano, A. Russo Rossi, V. Liso, G. Specchia (Hematology- University of Bari, Bari, Italy) |
| 0145 | PROTEOMIC PATTERNS AND GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION S. Bellesi, P. Chiusolo, C. Fanali, S. Giammarco, S. Sica, R. Inzitari, F. Iavarone, G. Leone, M. Castagnola (Università Cattolica S. Cuore, Rome, Italy) |
| 0146 | CD8 DEPLETED DLI RECONSTITUTE FULL DONOR T-CELL CHIMERISM AND REPLENISH THE CD52-POSITIVE CD4 T CELL POOL AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION E.M. Wagner, A. Lay, T. Schmitt, J. Hemmerling, D. Wolff, K. Bender, C. Huber,W. Herr, R.G. Meyer (University Medical Center Mainz, Mainz, Germany) |
| 0147 | CYCLOSPORINE DOSE INTENSITY IS A CRITICAL DETERMINANT OF OUTCOME AFTER A REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT C. Craddock, S. Nagra, P. Moss, M. Cook (Queen Elizabeth Hospital, Birmingham, United Kingdom) |
| 0148 | IMPACT OF MINOR HISTOCOMPATIBILITY ANTIGEN MISMATCHES ON GRAFT-VERSUS-HOST DISEASE IN NON-MYELOABLATIVE OR REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION C. Carniti, F. Spina, L. Farina, A. Raganato, A. Vendramin, S. Di Terlizzi, A. Dodero, N. Frungillo, P. Corradini (Istituto Nazionale dei Tumori, Milan, Italy) |
| 0149 | CHARACTERIZATION OF T CELL RECEPTOR BETA REPERTOIRE IN T CELL POPULATION ASSOCIATED WITH GRAFT-VERSUS-HOST AND GRAFT-VERSUS-LEUKEMIA EFFECT V. Foltankova, E. Matejkova, M. Bartos, M. Dendis, J. Mayer, R. Hajek, J. Michalek (Masaryk University, Faculty of Medicine, Brno, Czech Republic) |
| 0150 | RETROSPECTIVE SINGLE CENTER ANALYSIS OF PENTOSTATIN FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE T. Schmitt, S. Dietrich, T. Luft, U. Hegenbart, A.D. Ho, P. Dreger (Universitätsklinikum Heidelberg, Heidelberg, Germany) |
| 0151 | GENETIC MISMATCH IN GSTT1 IS ASSOCIATED WITH HEPATIC ACUTE GRAFT VERSUS HOST DISEASE (GVHD) IN ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) I. Tallon-Ruiz (Hospital Virgen del Rocio, Sevilla, Spain) |
| 0152 | SECONDARY PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A RETROSPECTIVE STUDY OF 73 CASES AT A SINGLE INSTITUTION J-B. Wang, F. Liu (Beijing Daopei Hospital, Beijing, China) |
| 0153 | NATURAL KILLER CELL NUMBERS POST STEM CELL TRANSPLANT ARE STRONGLY ASSOCIATED WITH DONOR CHIMERISM AND ARE INCREASED FOLLOWING UMBILICAL CORD STEM CELL TRANSPLANT U.A. Khan, O. Najam, A. Bastih, R.W. Critchley, N. Yonan, J. Fildes,R. Wynn (The Transplant Centre, Manchester, United Kingdom) |
| 0154 | ASSOCIATION BETWEEN PLASMA LEVEL CHANGES OF ENDOTHELIAL INJURY MARKERS AND GRAFT VERSUS HOST DISEASE IN PATIENTS TREATED WITH ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION A. Czyz, A. Anna, A. Blazejczak, E. Hanszke, D. Dytfeld, K. Zawilska, M. Komarnicki (University of Medical Sciences, Poznan, Poland) |
| 0155 | HUMAN MESENCHYMAL STROMAL CELLS EXPANDED WITH HUMAN PLATELET LYSATE ARE SAFE AND EFFECTIVE FOR THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE C. Capelli, M. Introna, C. Micò, A. Algarotti, A. Grassi, A. Salvadè, G. Gaipa, D. Belotti, P. Perseghin, G. D'Amico, A. Rovelli, A. Balduzzi, J. Golay, A. Biondi, A. Rambaldi, E. Biagi (Lab.Cellular Therapy G.Lanzani, Bergamo, Italy) |
| 0156 | HIGH CYTOMEGALOVIRUS (CMV)-SPECIFIC CD8+ TEMRA CONTENT IN DONOR GRAFT PREDICTS A LOW RISK OF CMV REACTIVATION FOLLOWING UNMANIPULATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION H. Xiao-Jun, X.H. Luo (Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China) |
STEM CELL TRANSPLANTATION – AUTOLOGOUS, DLI, MISCELLANEOUS
| 0158 | DONOR LYMPHOCYTE INFUSIONS FOR CHRONIC MYELOID LEUKAEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANT: PROGNOSTIC FACTORS FOR A 'PURE' GVL EFFECT ARE DIFFERENT ACCORDING TO THE STAGE OF RELAPSE |
|---|---|
| 0159 | EFFICACY OF RITUXIMAB AND DONOR LYMPHOCYTE INFUSIONS AS SALVAGE TREATMENT IN LYMPHOMA PATIENTS RELAPSED AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION |
| 0160 | ACUTE LUNG INJURY AFTER ALLOGENEIC HEMTOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IS ASSOCIATED WITH INFERIOR SURVIVAL - A RANDOMIZED TRIAL ON THE EFFECTS OF EARLY NON-INVASIVE VENTILATION (NIV) |
| 0161 | THERAPEUTIC DRUG MONITORING IS AN IMPORTANT FACTOR DURING IV BUSULFAN TREATMENT |
| 0162 | TOTAL BODY IRRADIATION (TBI) AND THIOTEPA AS CONDITIONING TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH FOLLICULAR LYMPHOMA M. Capponi, F. Falzetti, L. Flenghi, M. Di Ianni, P. Minga, F. Falcinelli (Istituto di Ematologia, Perugia, Italy) |
| 0163 | RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR SIGNIFICANTLY DECREASES THE EXPRESSION OF CXCR3 AND CCR6 ON T CELLS AND PREFERENTIALLY INDUCES TH CELLS TO A TH17 PHENOTYPE IN PERIPHERAL BLOOD HARVESTS L.X. Sun, H.Y. Ren (Peking University First Hospital, Beijing, China) |
| 0164 | REDUCED INTENSITY CONDITIONING UMBILICAL CORD BLOOD TRANSPLANTATION (RIC-UCBT) IN ADULTS: AGE, DISEASE STATUS AND INFECTIOUS COMPLICATIONS ARE IMPORTANT RISK FACTORS FOR OUTCOME S. Fürst, C. Faucher, J. El Cheikh, J.M. Boher, P. Ladaique, C. Lemarié, N. Vey, R. Bouabdallah, A.M. Stoppa, H. De Lavallade, M. Mohty, C. Chabannon, D. Blaise (Institut Paoli-Calmettes, Marseille, France) |
| 0165 | CLINICAL IMPLICATIONS OF PULMONARY FUNCTION TESTS IN ALLOGENEIC STEM CELL RECIPIENTS S.K. Sohn, J.H. Moon, J.H. Park (Kyungpook National University Hospital, Daegu, South-Korea) |
| 0166 | HUMAN BONE MARROW AS SOURCE OF STEM CELLS FOR INTRAPANCREATIC TRANSPLANTATION IN IMMUNODEFICIENT MICE: EVIDENCE OF PANCREATIC-CELL LINEAGE COMMITMENT BY GENE EXPRESSION ANALYSIS M.T. Arce-Franco, J.M. Raya, M. Barajas, M.J. Dominguez-Luis, A.M. Herrera, A. Diaz-Martín, T. Martín-Santos, L. Morabito, M.J. Rodriguez-Salazar, J. Lopez-Fernandez (Hospital Universitario de Canarias, La Laguna, Spain) |
| 0167 | RESULT OF DOUBLE UNITS CORD BLOOD TRANSPLANTATION IN CHILDREN AND ASSOCIATION OF CFU-GM WITH THE DETERMINATION OF DOMINANCY H.J. Kang, K.H. Yoo, J.W. Lee, H. Kim, S.H. Lee, K.W. Sung, H.H. Koo, H.Y. Shin, H.S. Ahn (Seoul National University College of Medicine, Seoul, South-Korea) |
| 0168 | A PHASE I STUDY OF CLOFARABINE PLUS HIGH DOSE MELPHALAN AS A CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION M. Kirschbaum, A.S. Stein, R. Nakamura, A. Nademanee, L. Popplewell, M. Delioukina, R. Chen, D. Snyder, J. Conrad, P. Frankel, S. Forman (City of Hope National Cancer Center, Duarte, USA) |
| 0169 | PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) IN PATIENTS WITH LYMPHOMA TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY OR HIGH RISK DISEASE P.M. Stefani, U. Salvadori, M. Gottardi, S. Bissoli, F. Chierichetti, F. Gherlinzoni (Struttura Complessa di Ematologia, Treviso, Italy) |
| 0170 | BOTH IL-3 AND IL-6 ARE NECESSARY FOR BETTER EX VIVO EXPANSION OF CD133+ CELLS FROM UMBILICAL CORD BLOOD P. Bordeaux-Rego, A. Luzo, F.F. Costa, S.T.O. Saad, D.P. Crosara-Alberto (University of Campinas-Brazil, Campinas, Brazil) |
| 0171 | TRACKING OF DONOR TYPE GREN FLUORESCENT (GFP) AND LUCIFERASE (LUC) POSITIVE MARROW MONONUCLEAR OR MESENCHYMAL STEM CELLS IN POSTMORTEM SPINAL CORD HISTOPATHOLOGICAL SECTIONS FOR DETERMINATION OF REGENERATION IN A SPINAL CORD INJURY MODEL M. Beksac, I. Kuzu, M. Ozdemir, M. Ayten, K. Dalva, D. Uçkan, E. Kiliç, A. Attar, M. Beksac, Y. Kanpolat (Ankara University, Ankara, Turkey) |
| 0172 | TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) AS CONDITIONING REGIMEN FOR LYMPHOMA TREATMENT WITH AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) A.M. Carella, G. Palumbo, E. Merla, F. Ferrara, M. Greco, M. Dell'Olio, P. Scalzulli, G. Pisapia, P. Mazza, A. Guarini, A. Iacobazzi, P. Musto, S. Capalbo, N. Cascavilla (Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy) |
NOVEL THERAPEUTICS, TARGETED THERAPIES AND GENE THERAPY - PRECLINICAL & CLINICAL
| 0173 | ACE-0, A SOLUBLE ACTIVIN RECEPTOR-LIKE KINASE FUSION PROTEIN, IS A NOVEL ANTI-ANGIOGENIC AGENT |
|---|---|
| 0174 | PHARMACOLOGY OF CPX-351: A NANO-SCALE LIPOSOMAL FIXED MOLAR RATIO CYTARABINE-DAUNORUBICIN FOR PATIENTS WITH ADVANCED LEUKEMIA |
| 0175 | UTILIZING CELL-BASED SCREENING TO IDENTIFY NOVEL USES FOR EXISTING DRUGS: INDUCING SPECIFIC APOPTOSIS OF B-CELL LYMPHOCYTES |
| 0176 | HUMAN MESENCHYMAL STROMAL CELLS DISPLAY SKEWED ADHESION RECEPTOR USAGE FOR ARREST ON ENDOTHELIAL CELLS AND TRANSENDOTHELIAL MIGRATION, FAVOURING E-SELECTIN, BETA1 INTEGRINS, AND A PLEIOTROPIC CHEMOKINE RESPONSE: IMPLICATIONS FOR CELLULAR THERAPY WITH MSC |
| 0177 | A NOVEL RECOMBINANT BISPECIFIC ANTIBODY TARGETING HM1.24 ON MULTIPLE MYELOMA M. Peipp, C. Ehlert, M. Staudinger, A. Muskulus, C. Kellner, S. Mohseni Nodehi, P. Glorius, M. Dechant, R. Burger, J. Brünke, G.H. Fey, M. Gramatzki, R. Repp (Christian-Albrechts-University Kiel, Kiel, Germany) |
| 0178 | D EPITOPE EVALUATION OF THE 25 RHESUS D SPECIFIC IGG1 ANTIBODIES IN ROZROLIMUPAB (SYM001), THE FIRST RECOMBINANT POLYCLONAL ANTIBODY PRODUCT M. Wikén, A.M. Valentin Jensen, P.S. Andersen, W.A. Flegel (Biovitrum, Stockholm, Sweden) |
| 0179 | IBRITUMOMAB TIUXETAN IN LYMPHOMA- A SINGLE CENTRE EXPERIENCE FROM KUWAIT P. Nair, A.l. Shemmari, H. Chokshi, S. Sajnani (Kuwait Cancer Control Centre, Calicut, Kerala, India) |
| 0180 | THE CXCR4 ANTAGONIST 4F-BENZOYL-TN14003 STIMULATES THE EXIT OF HEMATOPIETIC CELLS AND THE REGENERATION OF THE BONE MARROW FOLLOWING TRANSPLANTATION A. Peled, M. Abraham, K. Beider, A. Nagler, Z. Zipori, E. Eizenberg (Hadassah Hebrew University Hospital, Jerusalem, Israel) |
| 0181 | DEXAMETHASONE AND DASATINIB INDUCE SYNERGISTIC INHIBITION OF MAJOR T CELL EFFECTOR FUNCTIONS R. Seggewiss, C. Dix, H. Einsele (University of Würzburg, Würzburg, Germany) |
| 0182 | EX VIVO ACTIVITY OF SGI-17, A POTENT SMALL MOLECULE PIM KINASE INHIBITOR, IN PRIMARY HUMAN LEUKEMIA AND LYMPHOMA CELLS P. Taverna, G. Berk, S. Kanekal, D. Bearss (SuperGen, Dublin, USA) |
| 0183 | IN VITRO ANALYSIS OF NOVEL ANTI-CD20 ANTIBODY GA101 AND RITUXIMAB IN MANTLE CELL LYMPHOMA D. Heinrich, K. Decheva, M. Weinkauf, G. Hutter, Y. Zimmermann, T. Weiglein, W. Hiddemann, M. Dreyling (Department of Medicine III, University Hospital Munich - Campus Großhadern, Munich, Germany) |
| 0184 | EFFECTS OF THE PI3 KINASE/MTOR INHIBITOR NVP-BEZ235 ON GROWTH AND IGE-DEPENDENT MEDIATOR RELEASE IN HUMAN BASOPHILS AND MAST CELLS K. Blatt (Medical University of Vienna, Austria, Vienna, Austria) |
| 0185 | EFFECT OF THE NON-PEPTIDE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (PROMACTA_/REVOLADE(TM)) ONBONE MARROW CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES B. Will, J.P. Luciano, M. Kawahara, C. Erickson-Miller, A. Verma, M. Aivado, U. Steidl (Albert Einstein College of Medicine, New York, USA) |
| 0186 | FETAL HEMOGLOBIN (HBF) MODULATION BY NOVEL ALKYLATING AGENTS IN HUMAN ERYTHROID CELLS; SYNERGISTIC EFFECTS WITH ESTABLISHED HBF-INDUCING AGENTS I. Chiotoglou, M. Samara, G. Paterakis, S. Likousi, Z. Iakovidou, E. Mioglou, D. Mourelatos, I. Marinou, P. Liakos, P. Kollia (University of Thessaly, Larissa, Greece) |
| 0187 | LENALIDOMIDE IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA A. Tempescul, J.C. Ianotto, G. Guillerm, C. Berthou (University Hospital Brest, Brest, France) |
| 0188 | BINDING OF THE RECOMBINANT POLYCLONAL ANTI-D PRODUCT ROZROLIMUPAB (SYM001) AND PLASMA DERIVED ANTI-D TO RHD VARIANTS M. Wikén, A.M. Valentin Jensen, P.S. Andersen, W.A. Flegel (Biovitrum, Stockholm, Sweden) |
| 0189 | CD200, A CELL SURFACE PROTEIN WITH IMMUNOREGULATORY FUNCTION, IS A NEW POTENTIAL TARGET FOR HEMATOLOGIC MALIGNANCIES IMMUNOTHERAPY L. Brunetti, E. Abate, M. Gorrese, M. Raia, C. Pascariello, A. Gravetti, G. Scalia, L. Del Vecchio (Ceinge Institute, Naples, Italy) |
| 0190 | SUCCESSFUL TREATMENT WITH BEVACIZUMAB IN POEMSSYNDROME V. Buxhofer-Ausch, B. Gisslinger, G. Stangl, H. Rauschka, H. Gisslinger (Donauspital, Wien, Austria) |
| 0191 | SLUG AND ERK (P42-44): NEW TARGETS IN CHRONIC MYELOID LEUKEMIA THERAPY M. Mancini, S. Petta, V. Corradi, G. Martinelli, E. Barbieri, M.A. Santucci (Istituto di Ematologia e Oncologia Medica L. e A. Seràgnoli, Bologna, Italy) |
| 0192 | CMC-54, AN ANTI-CD22 IMMUNO-CONJUGATE OF CALICHEAMICIN, DECREASES THE LEVEL OF COMPLEMENT INHIBITORY FACTORS ON MALIGNANT B-CELL LYMPHOMA CELLS A. Takeshita, N. Yamakage, K. Shinjo, I. Hirano, T. Ono, H. Fujihara, H. Watanabe, K. Iino, D. Hashimoto, M. Maekawa, K. Ohnishi, R. Ohno (Hamamatsu University School of Medicine, Hamamatsu, Japan) |
RED BLOOD CELLS AND IRON I
| 0193 | EFFICACY AND SAFETY OF DEFERASIROX IN REDUCING MYOCARDIAL |
|---|---|
| 0194 | LABILE PLASMA IRON LEVELS IN HEAVILY IRON-OVERLOADED PATIENTS WITH TRANSFUSION-DEPENDENT ANAEMIAS IN RESPONSE TO DEFERASIROX THERAPY: RESULTS FROM THE LARGE-SCALE, PROSPECTIVE 1-YEAR EPIC TRIAL |
| 0195 | THE EFFICACY OF IRON CHELATOR REGIMES IN REDUCING CARDIAC AND HEPATIC IRON IN PATIENTS WITH THALASSAEMIA MAJOR: A CLINICAL OBSERVATIONAL STUDY |
| 0196 | INCREASED PLASMA LEVELS OF NGAL AND IL-18 CORRELATE WITH REDUCED GFR PROVIDING EVIDENCE OF TUBULOGLOMERULAR DEFECT IN PATIENTS WITH HBS/BETA-THALASSEMIA |
| 0197 | ANALYSIS OF IRON HOMEOSTASIS AND ERYTHROID ACTIVITY IN A COHORT OF LOW-RISK MYELODYSPLASTIC PATIENTS E. Messa, C. Maffè, G. Volpe, N. Campostrini, D. Gioia, A. Levis, D. Cilloni, D. Girelli, C. Camaschella, G. Saglio (University of Turin, Orbassano, Italy) |
| 0198 | MYOCARDIAL LESIONS AND IRON DEPOSITS AFTER TREATMENT WITH ANTHRACYCLINES A. Cascales, F. Pastor, B. Sanchez-Vega, J. Corral, V. Vicente, F. Ayala (Centro Hemodonacion, Murcia, Spain) |
| 0199 | ASSESSMENT OF SAFETY IN PATIENTS RECEIVING LONGER-TERM IRON CHELATION THERAPY WITH DEFERASIROX WHO HAD ACHIEVED SERUM FERRITIN LEVELS OF <1000 NG/ML DURING THE STUDY COURSE J.B. Porter, A. Piga, A. Cohen, J.M. Ford, J. Bodner, M.D. Cappellini (University College London, London, United Kingdom) |
| 0200 | SAFETY AND EFFICACY OF IRON CHELATION THERAPY WITH DEFERASIROX IN PATIENTS WITH SICKLE CELL DISEASE (SCD): 3.5-YEAR FOLLOW-UP E. Vichinsky, T. Coates, A.A. Thompson, F. Bernaudin, D. Lagrone, V. Dong, M.M. Heeney (Children's Hospital and Research Center Oakland, Oakland, USA) |
| 0201 | DEFERASIROX IN PAEDIATRIC PATIENTS WITH THALASSAEMIA MAJOR: 1-YEAR RESULTS FROM A LARGE PAEDIATRIC COHORT ENROLLED IN THE PROSPECTIVE, MULTICENTRE EPIC STUDY A. Filosa, M. Elalfy, C. Li, Y. Lai, L.L. Chan, P. Sutcharitchan, D. Habr,G. Domokos, B. Roubert, A. El-Beshlawy (Cardarelli Hospital, Naples, Italy) |
| 0202 | DELETION IN THE LDLR1 & 2 DOMAINS IN THE TMPRSS6 GENE IN A CHILD CAUSES IRIDA WITH EXTREMELY HIGH HEPCIDIN LEVEL I. Tchou, M. Diepold, M. Neerman-Arbez, P. Beris (Geneva University Hospital, Geneva, Switzerland) |
| 0203 | OUTCOMES OF PATIENTS WITH SICKLE CELL DISEASE ADMITTED TO THE INTENSIVE THERAPY UNIT - A SINGLE INSTITUTION EXPERIENCE C.J. Gardner, C. Bell, M. Allman, M. Ervine, S.L. Thein, M. Awogbade (King's College Hospital, London, United Kingdom) |
| 0204 | TREATMENT WITH DEFERASIROX EFFECTIVELY DECREASES IRON BURDEN IN PATIENTS WITH THALASSEMIA INTERMEDIA E. Voskaridou, M. Konstantinidou, M. Douskou, E. Plata, M. Papadakis, E.E. Delaki, D. Christoulas, E. Terpos (Thalassemia Center, Laikon General Hospital, Athens, Greece) |
| 0205 | ACUTE SPLENIC SEQUESTRATION IN SICKLE CELL DISEASE (SCD) V. Brousse, E. Lesprit, F. Bernaudin, M.H. Odievre, C. Guitton, B. Quinet, S. Dangiolo, M. De Montalembert (Hopital Necker, Paris, France) |
| 0206 | IRON CHELATION THERAPY WITH DEFERASIROX FOR TRANSFUSIONAL IRON-OVERLOADED PATIENTS WITH APLASTIC ANAEMIA AND OTHER RARE ANAEMIAS J.B. Porter, S.-S. Yoon, Z.X. Shen, S.L. Thein, K.-H. Lin, D. Habr, G. Domokos, B. Roubert, J.W. Lee (University College London, London, United Kingdom) |
| 0207 | A CLOSER LOOK AT CELLULAR IRON METABOLISM IN IRP2 DEFICIENT ERYTHROBLASTS M Schranzhofer, B Galy, M Schifrer, M Hentze, E Muellner, P Ponka (Jewish General Hospital, McGill University, Montreal, Canada) |
| 0209 | DEFERASIROX SIGNIFICANTLY REDUCES IRON BURDEN IN HEAVILY IRON-OVERLOADED PATIENTS WITH BETATHALASSAEMIA: 2.7 YEAR RESULTS FROM THE ESCALATOR STUDY A. Taher, A. El-Beshlawy, M. Elalfy, K. Al Zir, S. Daar, D. Habr, U. Kriemler- Krahn, B. Roubert, A. Al Jefri (American University of Beirut Medical Center, Beirut, Lebanon) |
RED BLOOD CELLS AND IRON II
| 0210 | DEFERASIROX FOR THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN SICKLE CELL ANEMIA: A 1-YR PROSPECTIVE STUDY |
|---|---|
| 0211 | HPLC QUANTITATION OF ALPHA-GLOBIN HEMOGLOBINOPATHIES IS INFLUENCED BY CONCURRENT ALPHA-THALASSEMIA |
| 0212 | GLUTATHIONE S TRANSFERASE GENE MUTATIONS AS THE CANDIDATE FACTOR RESPONSIBLE FOR THE OXIDATIVE STRESS BURDEN IN INDIAN HBE/B THALASSEMIA PATIENTS |
| 0213 | ALTERATIONS IN CONTRACTILE RESPONSE OF DETRUSOR SMOOTH MUSCLE OF SICKLE CELL DISEASE TRANSGENIC MICE |
| 0214 | DO WE HAVE TO RECONSIDER FERRITIN OPTIMAL LEVELS IN MULTITRANSFUSED THALASSAEMIA MAJOR PATIENTS? K. Farmaki, I. Tzoumari, Ch. Pappa (Thalassaemia Unit, Corith, Greece) |
| 0215 | TREATMENT WITH DEFERASIROX EFFECTIVELY DECREASES IRON BURDEN IN PATIENTS WITH SICKLE CELL SYNDROMES E. Voskaridou, M. Douskou, E. Plata, C. Papanikolaou, E.E. Delaki, D. Christoulas, E. Terpos (Thalassemia Center, Laikon General Hospital, Athens, Greece) |
| 0217 | RELEVANCE OF ALPHA HEMOGLOBIN STABILIZING PROTEIN POLYMORPHISMS IN SICKLE CELL DISEASE PATIENTS FROM OMAN V. Pathare, A. Al Zadjali, S. Alkindi, N. Huneini, S. Al Farsi, L. Misquith, J. Dennison, R. Krishnamoorthy (Sultan Qaboos University, Muscat, Oman) |
| 0218 | NON-TRANSFERRIN-BOUND IRON: A NOVEL INDICATOR OF IRON OVERLOAD IN PATIENTS WITH SICKLE CELL DISEASE A. Inati, K. Musallam, M. Taha, F. Ziade, A. Taher (Rafik Hariri University Hospital, Beirut, Lebanon) |
| 0219 | OUTCOME OF PREGNANCY IN SICKLE CELL SYNDROMES. A SINGLE CENTER STUDY E. Plata (Laiko General Hospital, Athens, Greece) |
| 0220 | INCREASED PLATELET AND NEUTROPHIL ADHESION IN SICKLE CELL DISEASE CORRELATES DIFFERENTLY TO VARIABLE LEVELS OF HEMOGLOBIN A M.A.C. Bezerra, C.F. Franco-Penteado, C. Lanaro, S. Gambero, K.Y. Fertrin, M.R.B. Mello, D.M. Albuquerque, S.T.O. Saad, A.S. Araujo, F.F. Costa (UNICAMP, Campinas, Brazil) |
| 0221 | IMPLEMENTATION, EFFICACY AND SAFETY OF A BLOOD CONSERVATION PROTOCOL IN PATIENTS UNDERGOING SURGERY FOR HIP FRACTURE REPAIR. AN ANALYSIS OF 399 CONSECUTIVE PROCEDURES J.A. García-Erce, J. Cuenca, S. Haman-Alcober, B. Soria, D. Rubio, A. Herrera, M. Muñoz (SALUD, Zaragoza, Spain) |
| 0222 | OXIDANT-ANTIOXIDANT SYSTEM AND LYMPHOCYTE DNA DAMAGE IN BETA THALASSEMIA CHILDREN M. Soker (Dicle University Faculty of Medicine, Diyarbakir, Turkey) |
| 0223 | DISORDERS OF GLUCOSE METABOLISM ARE A MAJOR ENDOCRINE COMPLICATION IN OMANI THALASSAEMICS S. Daar, N. Woodhouse, K. Panjwani, O. Elshafie, A.V. Pathare (Sultan Qaboos University, Muscat, Oman) |
| 0224 | OXYDATIVE STRESS AND ERYTHROPOIETIN REDUCTION DURING AND AFTER A FOURTEEN DAYS SCUBA DIVE B.M. Ricerca, L. Revelli, A.M. D'Amore, E. Di Stasio, S. Persichilli, G. Storti, C.P. Lombardi, J. Gervasoni, S. Vagnoni (Catholic University of Sacred Heart, Rome, Italy) |
| 0225 | ENDOSOMAL TRANSPORT OF TRANSFERRIN TO MITOCHONDRIA IS ESSENTIAL FOR EFFICIENT UTILIZATION OF IRON FOR HEME SYNTHESIS P. Ponka, A.-S. Zhang, T. Kahawita, O. Shirihai, D. Sheftel (McGill University, Montreal, Canada) |
PLATELETS & THROMBOCYTOPENIA I
| 0226 | REDUCED CORTICOSTEROID IN ADULTS WITH ITP RECEIVING ROMIPLOSTIM |
|---|---|
| 0227 | MULTICENTER STUDY OF LOW-DOSE ANTI-CD20 VELTUZUMAB FOR |
| 0228 | SAFETY AND EFFICACY OF LAPAROSCOPIC SPLENECTOMY IN PATIENTS WITH REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA. A LONG-TERM SURVEY |
| 0229 | USE OF FONDAPARINUX IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA |
| 0230 | THE HOSPITALIZATION NEED AND COST OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) TREATMENT: A MONOCENTRIC EVALUATION M. Ruggeri, S.F. Fortuna, F.R. Rodeghiero (San Bortolo Hospital, Vicenza, Italy) |
| 0231 | DURABLE AND OVERALL PLATELET RESPONSES IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) DURING LONG-TERM TREATMENT WITH ORAL ELTROMBOPAG BY SPLENECTOMY STATUS: THE RAISE STUDY R. Stasi, G. Cheng, M.N. Saleh, J. Bussel, S. Vasey, B. Mayer, M. Aivado, M. Arning, N.L. Stone (Regina Apostolorum Hospital, Alabano Laziale, Italy) |
| 0232 | STUDY OF THE IN VITRO EFFECT OF THE NONPEPTIDE THROMBOPOIETIN -RECEPTOR AGONIST SB-49711 (ELTROMBOPAG) ON MEGAKARYOPOIESIS OF PATIENTS WITH LOW/INTERMEDIATE-I RISK MYELODYSPLASTIC SYNDROME I. Mavroudi, M. Psyllaki, K. Pyrovolaki, G. Gvazava, C. Kalpadakis, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece) |
| 0233 | IMPROVEMENT IN FATIGUE AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH LONG-TERM ELTROMBOPAG THERAPY IN CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): RESULTS OF PHASE , DOUBLE-BLIND STUDY(RAISE) D. Provan, J.B. Bussel, G. Cheng, K.M. Grotzinger, M. Duh, J. Signorovitch, N.L. Stone, M. Aivado (Bart's and the London Queen Mary's School of Medicine and Dentistry, London, United Kingdom) |
| 0234 | USEFULNESS OF PRETEST CLINICAL SCORES ('4T'S) AND THEIR CORRELATION WITH THE RAPID ID-HEPARIN / PF4 ANTIBODY TESTING FOR THE DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA K. Mathur, L. Anderson, R. Green, R. Soutar (Scottish National Blood Transfusion Services, Glasgow, United Kingdom) |
| 0235 | PROSPECTIVE STUDY OF ABBREVIATED COURSE RITUXIMAB FOR AUTOIMMUNE HAEMATOLOGICAL DISORDERS REFRACTORY TO STANDARD IMMUNOSUPPRESSIVE THERAPY S.Z. He, D.A. Ritchie, B. Kuss, P. Macardle, K.E. Matoga, A.P. Grigg (The Royal Melbourne Hospital, Melbourne, Australia) |
| 0236 | CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPIES: THE PATIENTS' PERSPECTIVE ON BOTHERSOME EFFECTS R. Horblyuk, A. Matzdorff, T.M. Brown, K.M. Grotzinger, A. Brainsky (GlaxoSmithKline, Collegeville, USA) |
| 0237 | THROMBOPOIETIN RECEPTOR (CMPL) EXPRESSION IN INHERITED AND ACQUIRED PLATELET DISORDERS S. Vettore, R. Scandellari, M. Scapin, F. Tezza, M.L. Randi, F. Fabris (University of Padua Medical School, Padova, Italy) |
| 0238 | EFFICACY AND SAFETY OF INTRAVENOUS ANTI-D TREATMENT OF PATIENTS WITH REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA M. Mantzourani, S. Raptis, L. Dimitrakopoulou, T. Vassilakopoulos, M. Moschogianni, A. Katsandri, G. Pangalis, G. Vaiopoulos (National and Kapodistrian University of Athens, Goudi, Athens, Greece) |
| 0239 | IMPROVEMENT IN FATIGUE AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH LONG-TERM ELTROMBOPAG TREATMENT IN ADULTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): THE EXTEND STUDY J. Bussel, M. Saleh, A. Salama, K.M. Grotzinger, M. Duh, J. Signorovitch, N.L. Stone, M. Aivado (Weill Cornell Medical College, New York, USA) |
| 0240 | MICOPHENOLAT MOPHETIL IN THE TREATMENT OF REFRACTORY ADULT CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA M. Colovic, A. Vidovic, D. Tomin, I. Elezovic, N. Colovic, V. Palibrk (Institute of Hematology, Belgrade, Serbia) |
| 0241 | RITUXIMAB IN THE TREATMENT OF PATIENTS WITH REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA C. Montes-Gaisan, J. Nunez, L. Yanez, A. Bermudez, M. Ruiz, I. Olaya, J. Baro, E. Conde, A. Iriondo (Hospital Universitario Marqués de Valdecilla, Santander, Spain) |
| 0242 | CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA: PATIENT-PERCEIVED BURDEN K. Grotzinger, A. Matzdorff, T.M. Brown, R. Horblyuk, A. Brainsky (GlaxoSmithKline, Collegeville, USA) |
| 0243 | COMPARATIVE EVALUATION OF PLATELET COUNTING ON CELLAVISION DIFFMASTERTM OCTAVIA VERSUS OPTICAL FLUORESCENT PLATELET COUNTING ON SYSMEX XT-2000I AUTOMATED HEMATOLOGY ANALYZER A. Agorasti, E. Nikolakopoulou, E. Memet Ali, D. Konstantinidou (General Hospital of Xanthi, Xanthi, Greece) |
| 0244 | MEDICAL CONTRAINDICATIONS FOR SPLENECTOMY AMONG ADULTS WITH IMMUNE THROMBOCYTOPENIC PURPURA (ITP): DATA FROM THE GENERAL PRACTICE RESEARCH DATABASE (GPRD) W.M. Schoonen, L. Li, J.P. Fryzek, J.A. Kaye (Amgen Ltd, Uxbridge, Middlesex, United Kingdom) |
| 0245 | COMPARATIVE EVALUATION OF 4 AUTOMATED HEMATOLOGIC ANALYSERS (ADVIA120, PENTRA120DX, LH750, XE2100) WITH IMMUNOLOGICAL REFERENCE METHOD IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS M. Cedrone, F. Papa, S. Fenu, A. Chierichini, B. Anaclerico, V. Panetta, N. Antonucci, S. Cortese, M. Rongioletti, G. Liumbruno, L. Lenti, G. Avvisati, L. Annino (San Giovanni Hospital, Rome, Italy |
MYELODYSPLASTIC SYNDROMES I
| 0246 | LENALIDOMIDE ABROGATES THE CLONAL ADVANTAGE OF DEL(5Q) MDS STEM CELLS VIA ALTERATION OF NICHE INTERACTIONS |
|---|---|
| 0247 | EVALUATION OF COMORBIDITY AS PROGNOSTIC VARIABLE IN 419 PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A STUDY OF THE AUSTRIAN MDS WORKING GROUP |
| 0248 | A NOVEL RECURRENT GENETIC ABNORMALITY IN MYELODYSPLASTIC SYNDROMES (MDS): REARRANGEMENTS AND AMPLIFICATIONS OF IER3 |
| 0249 | NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING |
| 0250 | ABT 737 BCL-2 INHIBITOR TARGETS LEUKEMIC STEM CELLS IN MOUSE MODELS OF MYELOID (PRE)LEUKAEMIA R.-A. Padua, S. Beurlet, M. Saeed, N. Omidvar, P. Krief, D. Auboeuf, C. Le Pogam, M. Reboul, A. Soulié, A. Janin, M.-E. Noguera, P. Merlet, L. Sarda-Mentel, P. Fenaux, M. Fontenay, M. Konopleva, M. Andreeff, G. Mufti, F. Rassool, K. Mills, A. Tu, D. Voehringer, M. Pla, C. Chomienne (Institut Universitaire d'Hematologie, Paris, France) |
| 0251 | FISH PROBES DERIVED FROM ARRAY CGH (ACGH) REVEAL NOVEL CHROMOSOMAL LESIONS IN MDS PATIENTS WITH A NORMAL KARYOTYPE P. Bernasconi, I. Dambruoso, M. Boni, P.M. Cavigliano, S. Calatroni, I. Giardini, B. Rocca, R. Zappatore, C. Calvello, M. Caresana, M. Lazzarino (Division of Hematology, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy) |
| 0252 | ALLOGENIC STEM CELL TRANSPLANT IN MDS: RESULTS OF THE SPANISH REGISTRY O. Lopez-Villar, I. Cordoba, R. Martino, J.A. Perez-Simon, V. Gomez, T. Bernal, R.F. Duarte, M. Tormo, B. Xicoy, J. Bargay, E. Salido, L. Benlloch, G. Sanz, M.C. Del Cañizo, RE-SMD Registro Español de SMD, GETH Grupo Español de Transplante (Hospital Universitario de Salamanca, Salamanca, Spain) |
| 0253 | MICRORNA SIGNATURE OF CD34+ CELLS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH DEL(5Q) H. Bruchova, M. Merkerova, A. Vasikova, M. Belickova, J. Cermak (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) |
| 0254 | THE CAPACITY OF THE HYPOMETHYLATING AGENTS AZACYTIDINE AND DECITABINE TO INDUCE APOPTOSIS AND CELL CYCLE ARREST DEPENDS ON THE ACTIVATION OF THE DNA-DAMAGE RESPONSE PATHWAY S. Boehrer, L. Adès, C. Gardin, P. Fenaux, G. Kroemer (Hôpital Avicenne, Bobigny, France) |
| 0255 | TREATMENT OUTCOME ACCORDING TO PRETREATMENT RISK GROUP IN MDS PATIENTS WHO WERE TREATED WITH AZACITIDINE S.K. Sohn, J.H. Baek, J.H. Moon, J.H. Park, J.S. Chung, H.J. Won, S.M. Lee, Y.S. Joo, Y.K. Kim, H.J. Kim, D.Y. Jo, J.G. Kim, Y.S. Chae (Kyungpook National University Hospital, Daegu, South-Korea) |
| 0256 | RUNX1 MUTATIONS IN DE NOVO MDS AND CMML AT BOTH DIAGNOSIS AND AML TRANSFORMATION: A COMPARATIVE ANALYSIS ON 80 MATCHED PAIRED MARROW SAMPLES M.-C. Kuo, D.-C. Liang, C.-F. Huang, Y.-S. Shih, T.-L. Lin, J.-H. Wu, L.-Y. Shih (Chang Gung Memorial Hospital, Taipei, Taiwan) |
| 0257 | EXPRESSION OF P53 OR CYTOPLASMIC NUCLEOPHOSMINE ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION IN MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q) M.S. Jädersten, L. Saft, H. Garelius, R. Hast, L. Nilsson, J. Samuelsson, A. Porwit, E. Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden) |
| 0258 | DIFFERENT PATTERNS OF TELOMERASE REVERSE TRANSCRIPTASE (HTERT) MRNA VARIANT EXPRESSION PROFILES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES E. Verrou, V. Kaloutsi, E. Katodritou, V. Gastari, A. Banti, A. Nikitidou, V. Garypidou, K. Zervas, V. Kotoula (Theagenio Cancer Center, Thessaloniki, Greece) |
| 0259 | INCREASED FREQUENCY OF REGULATORY T-CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES C. Fozza, F. Longu, S. Contini, A. Galleu, P. Virdis, M.P. Simula,M. Longinotti (University of Sassari, Sassari, Italy) |
| 0260 | PHOSPHOINOSITIDE-PHOSPHOLIPASE C (PI-PLC) BETA1 AS A TARGET OF EPIGENETIC THERAPY IN MDS PATIENTS M. Follo, C. Finelli, S. Mongiorgi, C. Clissa, F. Chiarini, C. Bosi, M. Baccarani, L. Manzoli, G. Martinelli, A. Martelli, L. Cocco (University of Bologna, Bologna, Italy) |
| 0261 | HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROME - SYSTEMATIC REVIEW AND META-ANALYSIS R. Gurion, L. Vidal, A. Gafter-Gvili, Y. Belnik, M. Yeshurun, P. Raanani, O. Shpilberg (Rabin Medical Center, Petach Tikva, Israel) |
| 0263 | ARHGAP, A PARTNER OF ALPHA-CATENIN, MAY BE ALTERED EXPRESSED IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLATIC SYNDROMES LACKING 5Q DELETION K.S. Barcellos, S.M.B. Winnischofer, M. Lazarini, A.S.S. Duarte, F. Traina, F.F. Costa, S.T.O. Saad (State University of Campinas, Campinas, Campinas, Brazil) |
| 0265 | MESENCHYMAL STEM CELLS FROM 5Q- SYNDROME PATIENTS SHOW INCREASED EXPRESSION OF FGF4 AND IL32 IN COMPARISON TO OTHER MDS C.M. Santamaria, O. Lopez-Villar, F.M. Sanchez-Guijo, P. Hernandez-Campo, M.C. Del Cañizo (University Hospital of Salamanca, Salamanca, Spain) |
| 0266 | 'MONOCYTOSIS' THAT DEFINES CHRONIC MYELOMONOCYTIC LEUKEMIA INCLUDES A PROPORTION OF IMMATURE GRANULOCYTES WITH A DISTINCT MOLECULAR SIGNATURE A.J. Jacquel, N.D. Droin, M.C. Ciudad, C.R. Racoeur, V. Gelsi-Boyer, P. Calier, F. Girodon, G.L. Guery, B. Quesnel, P. Fenaux, I. Lafon, O. Beyne-Rauzy, A. Stamatoulas, F. Dreyfus, F. Boyer, B. Bonnotte, S. Raynaud, H. Cavé, A. Guercy-Bresler, C. Besson, C. Truntzer, F. Mugneret, D. Birnbaum, M. Fontenay, E.S. Solary (INSERM UMR86, Dijon, France) |
| 0267 | ISOLATED DEL 20Q DEFINES A SUBGROUP OF MDS PATIENTS WITH LOWER BLAST COUNTS AND MORE FREQUENT THROMBOCYTOPENIA T. Braun, S. De Botton, K. Guenda, G. Leroux, A.L. Taksin, S. Park, O. Beyne-Rauzy, S. Chevret, M. Fontenay, B. Cassinat, A. Lazareth, C. Terré, N. Vey, A. Guerci, F. Dreyfus, D. Bordessoule, A. Stamatoullas, S. Castaigne, V. Eclache, P. Fenaux, L. Adès (Groupe Francophone des Myelodysplasies (GFM), Bobigny, France) |
ACUTE MYELOID LEUKEMIA - BIOLOGY I
| 0268 | MODULATION OF MIR-449A EXPRESSION DECREASES CELL VIABILITY, INCREASES APOPTOSIS AND INDUCES DIFFERENTIATION IN EVI1 DEREGULATED LEUKEMIA CELLS |
|---|---|
| 0269 | RESTORING OF FOXO3 TRANSCRIPTION FACTOR ACTIVITY BY CHEMOTHERAPY INDUCES OF A QUIESCENT STATUS OF LEUKAEMIC PROGENITOR CELLS IN ACUTE MYELOID LEUKAEMIA |
| 0270 | PREVALENCE OF TET2 MUTATIONS IN DE NOVO ACUTE MYELOID LEUKAEMIA (AML) |
| 0271 | IDENTIFICATION OF FREQUENT GENOMIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA (AML) PATIENTS USING SINGLE NUCLEOTIDE POLYMORPHISM (SNP) ARRAYS |
| 0272 | THE PROGNOSTIC ROLE OF C-FLIP IN AML P. McLornan, M.F. McMullin, K.I. Mills, R.K. Hills, A. Gilkes, A.K. Burnett, P. Johnston, D.B. Longley (Centre for Cancer Research and Cell Biology, Belfast, Northern Ireland) |
| 0273 | SPECIFIC PATTERNS OF GLOBAL HDAC1 DYSLOCALIZATION IN ACUTE MYELOID LEUKEMIA L. Tickenbrock, H.U. Klein, C. Trento, A. Hascher, S. Göllner, N. Bäumer, R. Kuss, S. Agrawal-Singh, G. Bug, H.U. Serve, C. Thiede, G. Ehninger, U. Zur Stadt, M. McClelland, Y. Wang, A. Becker, S. Koschmieder, W.E. Berdel, M. Dugas, C. Müller-Tidow (University of Münster, Münster, Germany) |
| 0274 | GENE OVEREXPRESSION AND PROTEIN DELOCALIZATION OF PROTEINASE (PR3) MAY INCREASE CHEMOSENSITIVITY IN BLAST CELLS FROM CORE BINDING FACTOR LEUKEMIA PATIENTS D. Cilloni, S. Carturan, C. Maffè, M. Pautasso, F. Arruga, F. Messa, M. Pradotto, P. Fornaciari, I. Iacobucci, G. Martinelli, E. Messa, E. Bracco, G. Saglio (University of Turin, Turin, Italy) |
| 0275 | PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE BY REAL-TIME QUANTITATIVE PCR IN AML WITH CBFB - MYH11 REARRANGEMENT : THE FRENCH EXPERIENCE R. Guièze, A. Renneville, J.M. Cayuela, R. Ben Abdelali, N. Boissel, S. De Botton, M.T. Rubio, F. Mazingue, E.A. Macintyre, F. Sigaux, P. Fenaux, H. Dombret, C. Preudhomme (Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, Clermont-Ferrand, France) |
| 0276 | PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE MONITORING USING NPM1 MUTATION IN AML R.I. Itzykson, N. Boissel, P. Fenaux, B. Quesnel, J. Fernandes, S. Castaigne, J.V. Malfuson, S. Nguyen, C. Curtillet, M. Beaumont, J.P. Marolleau, Y. Perel, D. Caillot, Y. Bertrand, S. Glaisner, C. Pautas, C. Preudhomme, A. Renneville(CHRU Lille, Lille, France) |
| 0277 | THE AMP-KINASE AGONIST METFORMIN HAS TUMOR SUPPRESSOR ACTIVITY IN ACUTE MYELOID LEUKEMIA A.S. Green, L. Willems, N. Chapuis, V. Bardet, S. Park, M. Foretz, B. Viollet, N. Dedhin, N. Azar, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary, J. Tamburini (Institut Cochin, Paris, France) |
| 0278 | SUPPRESSOR OF CYTOKINE SIGNALING (SOCS1) IS INDUCED BY FLT3-ITD IN HEMATOPOIETIC STEM AND PROGENITOR CELLS AND COOPERATES IN LEUKEMOGENESIS H. Brandts, P. Kumar Reddy Nagaruri Gonchi, B. August, H. Serve (Goethe-University Frankfurt, Frankfurt, Germany) |
| 0279 | A SINGLE 8-COLOR FLOW-CYTOMETRIC IMMUNOSTAINING ALLOWS DELINEATION OF BOTH TYPICAL MYELOID AND LYMPHOID ACUTE LEUKEMIA AND UNDIFFERENCIATED/IMMATURE ACUTE LEUKEMIA (ON BEHALF OF THE EUROFLOW CONSORTIUM) L.L. Lhermitte, M. Bruggemann, V. Asnafi, Q. Lecrevisse, L. Sedek, S. Böttcher, E. Mejstrikova, T. Kalina, P. Lucio, A. Mendonça, J. Flores, V.H.J. van der Velden, J. te Marvelde, M. Cullen, S.J. Richard, T. Szczepanski, E. Macintyre, E.S. da Costa1, J.J.M van Dongen, A. Orfao (Paris V, APHP, Hopital Necker, Paris, France) |
| 0280 | EXPRESSION, FUNCTION AND REGULATION OF AUTOTAXIN, A RELEVANT MOTILITY AND SURVIVAL FACTOR, IN FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA AND PRIMARY HEMATOPOIETIC STEM CELLS C.O. Ortlepp, C. Steudel, S. Koch, A. Jacobi, M. Ryser, S. Brenner, M. Bornhäuser, G. Ehninger, C. Thiede (University Hospital Dresden, Dresden, Germany) |
| 0281 | A MOLECUALR CIRCUITRY COMPRISING MICRORNA-22, C/EBPA AND E2F1 IN GRANULOPOIESIS AND IN ACUTE MYELOID LEUKEMIA A. Pulikkan, V. Dengler, P.S. Peramangalam, A. Peerzada, C. Muller Tidow, S.K. Bohlander, D.G. Tenen, G. Behre (Landeszentrum fur Zell und Genetherapie, Halle, Germany) |
| 0282 | IMMUNOPHENOTYPIC CHARACTERIZATION OF CD34+/CD38- AML PROGENITOR CELLS AND THEIR RESPONSE TO VARIOUS DRUGS H. Herrmann, C. Baumgartner, W.R. Sperr, S. Holmes, P. Valent (Medical University of Vienna, Vienna, Austria) |
| 0283 | RETROVIRAL INTEGRATION MUTAGENESIS IN MICE AS A PLATFORM FOR IDENTIFICATION OF CRITICAL TUMOR SUPPRESSOR GENES IN HUMAN MYELOID DISORDERS R. Beekman, M. Valkhof, E. Taskesen, S.J. Erkeland, I.P. Touw (ErasmusMC, Rotterdam, The Netherlands) |
ACUTE MYELOID LEUKEMIA - BIOLOGY II
| 0284 | THE FAVORABLE IMPACT OF CEBPA MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IS ONLY OBSERVED IN THE ABSENCE OF ASSOCIATED CYTOGENETIC ABNORMALITIES AND FLT3 INTERNAL DUPLICATION (FLT3-ITD) (FOR THE ACUTE LEUKEMIA FRENCH ASSOCIATION ALFA GROUP) |
|---|---|
| 0285 | DIFFERENTIAL EXPRESSION OF NATURAL CYTOTOXICITY RECEPTORS (NCRS) IN CD56-POSITIVE ACUTE MYELOID LEUKEMIAS |
| 0286 | COOPERATING MUTATIONS IN DE NOVO AML WITH MLLPARTIAL TANDEM DUPLICATION AT DIAGNOSIS AND RELAPSE |
| 0287 | NUP98 FUSION PROTEINS. NEW INSIGHTS INTO SUB-CELLULAR LOCALIZATION AND INTERACTION WITH NUCLEO-CYTOPLASMIC TRAFFIC ELEMENTS |
| 0288 | FLOW CYTOMETRIC PROTEIN EXPRESSION PROFILING AS A POTENTIAL APPROACH FOR DEVELOPING AN ALTERNATIVE CLASSIFICATION OF ACUTE MYELOID LEUKAEMIA A.R. Hussein, S.J. Richards (Universiti sains Malaysia, Kubang Kerian, Malaysia) |
| 0289 | GENOME PROFILING OF NORMAL KARYOTYPE AML WITH HIGH DENSITY ARRAY COMPARATIVE GENOME HYBRIDISATION A. Chanalaris, C. Grace, R. Gale, D. Linch, E.P. Nacheva (UCL Medical School, London, United Kingdom) |
| 0290 | BOTH SEPT2 AND MLL ARE DOWN-REGULATED IN MLL-SEPT2 THERAPY-RELATED MYELOID NEOPLASIA N. Cerveira, J. Santos, S. Bizarro, V. Costa, F. Ribeiro, S. Lisboa, C. Correia, L. Torres, J. Vieira, S. Snidjer, J. Mariz, L. Norton, C. Mellink, A. Buijs, M. Teixeira (Portuguese Oncology Institute, Porto, Portugal) |
| 0291 | METHYLATION ANALYSIS OF THE SNRPN AND MEG3 IMPRINTED GENES IN ACUTE MYELOID LEUKEMIA PATIENTS L. Benetatos, A. Dasoula, E. Hatzimichael, G. Dranitsaris, M. Voukelatou, S. Tsiara, I. Georgiou, K. Bourantas (University Hospital of Ioannina, Ioannina, Greece) |
| 0292 | GENE EXPRESSION PROFILE MIGHT PREDICT PROGNOSIS IN PATIENTS WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA (AML) LACKING NPM1 AND FLT3 MUTATIONS M. Camos, S.G. Kalko, M. Torrebadell, M. Pratcorona, M. Rozman, M. Díaz-Beyá, D. Costa, A. Carrió, E. Campo, E. Montserrat, J. Esteve (Hospital Clinic. Hematology Lab, Hospital Sant Joan de Deu., Barcelona, Spain) |
| 0293 | SURVIVIN GENE EXPRESSION SIGNIFICANTLY CORRELATES WITH CLINICAL OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN ASSOCIATION WITH MDR1/P-GLYCOPROTEIN OVEREXPRESSION AND FLT3-ITD G. Balatzenko, A. Stoimenov, B. Spassov, V. Nikolova, M. Guenova, S. Konstantinov (National Haematological Hospital, Sofia, Bulgaria) |
| 0294 | GENE TARGETS OF ETV6-NTRK3 FUSION A.F. MacLeod, S. Chen, B. Schneider, S. Nagel, M. Kaufmann, H.G. Drexler (DSMZ, Brainschweig, Germany) |
| 0295 | A HYPOTHETICAL-MATHEMATICAL MODEL OF ACUTE MYELOID LEUKEMIA PATHOGENESIS A.M. Cucuianu, R. Precup (”Ion Chiricuta” Cancer Institute, Cluj-Napoca, Romania) |
| 0296 | PROGNOSTIC VALUE OF IMMUNOPHENOTYPE IN AML PATIENTS WITH NPM1 MUTATION M.T. Gomez Casares, A. Lemes, N. Navarro, J.D. González San Miguel, S. Fumero, J.M. Bosch, P. Martín, M.D. Fiuza, C.E. López, H. Luzardo, S. De la Iglesia, T. Molero (Hospital U. de GC Dr. Negrín, Las Palmas de GC, Spain) |
| 0297 | FLT3 ANTIGEN EXPRESSION IN ACUTE LEUKAEMIA USING FLOW CYTOMETRY S. Hassan, M. Leung, C. Ridler, C. Stephens, M. Macey, M. Jenner, S. Agrawal (St Bartholomew's Hospital, London, United Kingdom) |
| 0298 | QUANTITATIVE ASSESSMENT OF WT1 EXPRESSION: A USEFUL TOOL FOR MONITORING MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA PATIENTS F. Salmi, E. Ottaviani, C. Papayannidis, S. Paolini, B. Lama, D. Cilloni, F. Messa, N. Testoni, N. Vianelli, C. Finelli, I. Iacobucci, M. Baccarani, G. Martinelli, A. Curti (Department of Hematology/Oncology “Seràgnoli”, University of Bologna, Bologna, Italy) |
| 0299 | THE DELETION OF THE PROLINE-RICH REGION OF HOXB4 IS ASSOCIATED WITH MYELOID LEUKEMIA IN A MOUSE MODEL M. Cusan, A.J. Deshpande, V. Vijay, W. Wolfgang, L. Quintanilla-Martinez, K. Keith, C. Christian, M. Michaela (Klinikum Grosshadern, Munich, Germany) |
ACUTE MYELOID LEUKEMIA – CLINICAL I
| 0300 | CONTINUOUS SEQUENTIAL INFUSION OF FLUDARABINE AND CYTARABINE FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) SECONDARY TO MYELODYSPLASTIC SYNDROME (MDS) |
|---|---|
| 0301 | INFLUENCE OF HIGH EXPRESSION OF SMAC/DIABLO PROTEIN ON CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA PATIENTS |
| 0303 | LONG-TERM MOLECULAR COMPLETE REMISSION WITH PULSED ATRA AS SINGLE AGENT IN PML-RAR-ALPHA-POSITIVE ACUTE PROMYELOCYTIC LEUKEMIA |
| 0304 | A LUMINESCENT WHOLE CELL BACTERIAL BIOSENSOR FOR RAPID PRE-SCREENING OF CHEMOTHERAPY EFFICACY |
| 0305 | INDUCTION INTENSIFIED REGIMENS INCLUDING FLUDARABINE OR GEMTUZUMAB-OZOGAMICIN FOR ACUTE MYELOID LEUKEMIA PATIENTS: COMPARISON BY RESPONSE AND FOLLOW-UP C. Papayannidis, C. Candoni, P. Paolini, E. Ottaviani, I. Iacobucci, M. Rondoni, M. Malagola, P.P. Piccaluga, R. Fanin, G. Visani, M. Baccarani, D. Russo, G. Martinelli (Department of Hematology/ Oncology “Seràgnoli”, University of Bologna, Bologna, Italy) |
| 0306 | PROGNOSTIC SIGNIFICANCE OF FLT3/ITD MUTATION AND ABCB1 GENE POLYMORPHISMS IN CORE BINDING FACTOR (CBF)-ACUTE MYELOID LEUKEMIA (AML) Y.K. Kim, H.N. Kim, I.K. Lee, S.M. Bang, H.J. Kim, D.Y. Jo, J.H. Won, J.Y. Kwak, M.R. Park, J.S. Ahn, D.H. Yang, J.J. Lee, H.J. Kim (Chonnam National University Medical School, Gwangju, South-Korea) |
| 0307 | LAROMUSTINE INDUCES REMISSIONS IN ELDERLY POOR RISK AML PATIENTS WITH ADVERSE CYTOGENETICS AND DEMONSTRATES SIGNIFICANTLY IMPROVED SURVIVAL IN A HISTORICAL COMPARISON WITH PATIENTS TREATED IN THE UK NCRI AML14 TRIAL K. Hills, S. O'Brien, G. Schiller, V. Karsten, F. Giles, A. Burnett (Cardiff University School of Medicine, Cardiff, United Kingdom) |
| 0308 | RASGRP1/APTX RATIO IS A STRONG BIOMARKER WHICH PREDICTS RESPONSE TO THERAPY WITH TIPIFARNIB PLUS BORTEZOMIB IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) C. Papayannidis, P. Paolini, E. Ottaviani, I. Iacobucci, F. Salmi, B. Lama, A. Curti, S. Parisi, D. Cilloni, G. Saglio, C. Candoni, F. Morabito, M. Raponi, M. Baccarani, G. Martinelli (Department of Hematology/ Oncology “Seràgnoli”, University of Bologna, Bologna, Italy) |
| 0309 | BODY MASS INDEX IS AN INDEPENDENT PREDICTOR OF DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA R. Jeddi, H. Ghédira, S. Mnif, R. Ben Amor, L. Aissaoui, K. Kacem, W. Bouteraâ, R. Ben Lakhal, A. Saad, H. Ben Abid, Z. Belhadjali, B. Meddeb, Z. Belhadjali, Z. Belhadjali (Aziza Othmana University Hospital, Tunis, Tunisia) |
| 0310 | A PHASE I STUDY WITH CP-4055 AND IDARUBICIN IN PATIENTS WITH REFRACTORY/RELAPSED AML S. O’Brien, D. Rizzieri, S. Padmanabhan, F. Ravandi, T.F. Jacobsen, K. Staudacher, B.I. Nilsson, F.J. Giles (University of Texas, M.D. Anderson Cancer Center, Houston, USA) |
| 0311 | CNS MANIFESTION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SCHEDULED FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION M. Bommer, S. Von Harsdorf, D. Bunjes, H. Doehner, M. Ringhoffer (University of Ulm, Ulm, Germany) |
| 0312 | FLAIE (FLUDARABINE, CYTARABINE, IDARUBICIN AND ETOPOSIDE) AS INDUCTION CHEMOTHERAPY OF ADULT ACUTE MYELOID LEUKEMIA. A PILOT STUDY REPORT A. Candoni, E. Simeone, A. Michelutti, D. Damiani, D. Russo, R. Fanin (Division of Hematology, Udine, Italy) |
| 0313 | INDUCTION THERAPY WITH '3+7' CHEMOTHERAPY PLUS ATRA FOLLOWED BY CONSOLIDATIONS WITH THREE COURSES OF IDARUBICIN ALONE AND MAINTENANCE THERAPY WITH ATRA IN NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) HAS AN EXCELLENT LEUKEMIA-FREE SURVIVAL BUT MINIMAL TOXICITY IN LOW AND INTERMEDIATE RISK GROU Y.C. Mun, M.Y. Choi, E.K. Cho, J.H. Lee, D.Y. Jo, I.H. Kim, S.M. Bang, S.S. Yoon, S.Y. Park, B.K. Kim, H. Kim, Y.J. Min, J.H. Park, J.J. Seo, H.N. Moon, M.H. Lee, C.S. Kim, W.S. Lee, Y.D. Joo, S.Y. Chung, D.Y. Oh, D.Y. Zang, K.H. Lee, M.S. Hyun, H.S. Song, H.S. Kim, S.H. Kim, H.C. Kwon, H.J. Kim, M.J. Ahn, J.S. Ahn (Ewha Womans University School of Medicine, Seoul, South-Korea) |
| 0314 | MORPHOLOGIC AND MOLECULAR CHARACTERIZATION OF LEUKEMIC TUMORS IN THE BREAST: IMPLICATIONS FOR RESISTANCE TO CHEMOTHERAPY I. Cunningham, Cordon-Cardo's (Columbia University, New York, USA) |
CHRONIC MYELOID LEUKEMIA - BIOLOGY
| 0315 | FINAL RESULTS: RESPONSE PREDICTION IN IMATINIB-TREATED CML BY EXPRESSION PROFILING |
|---|---|
| 0316 | CD34+ OBTAINED FROM HIGH SOKAL RISK CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) EXPRESSES GENE PROFILES (GEP) SIGNIFICANTLY DIFFERENT FROM CD34+ OBTAINED FROM LOW AND INTERMEDIATE SOKAL RISK PATIENTS |
| 0317 | EVALUATION OF THE PROTEASOMAL EFFECTS OF TYROSINE KINASE INHIBITORS AND BORTEZOMIB IN CHRONIC MYELOID LEUKAEMIA |
| 0318 | DELETIONS OF THE DERIVATIVE CHROMOSOME 9 DO NOT INFLUENCE THE OUTCOME OF CHRONIC MYELOID LEUKEMIA IN EARLY CHRONIC PHASE TREATED WITH IMATINIB MESYLATE: A GIMEMA CML WP ANALYSIS OF 521 CONSECUTIVE PATIENTS |
| 0319 | PRESENCE OF BCR-ABL POSITIVE CELLS AND DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA (CML) IN IMMUNE SUPPRESSED ORGAN TRANSPLANT (SOT) RECIPIENTS P. le Coutre, P. Reinke, R. Neuhaus, R. Trappe, F. Ringel, M. Lalancette, P. Hemmati, B. Dörken, P. Daniel (Charité Universitätsmedizin Berlin, Berlin, Germany) |
| 0320 | THE ROLE OF THE FANCONI ANEMIA D (FANCD2) PROTEIN IN BCR/ABL-MEDIATED LEUKEMOGENESIS T. Stoklosa, M. Koptyra, G. Hoser, E. Glodkowska, I. Seferynska, T. Skorski (The Medical University of Warsaw, Warsaw, Poland) |
| 0321 | BCR-ABL ONCOPROTEIN MODULATES MIRNA INVOLVED IN APOPTOSIS REGULATION A.F. Ferreira, W.A. Silva-Jr, I.T. Silva, R. Azevedo, R. Tognon, M.A. Zanichelli, N. Hamerschlak, G.P. Amarante-Mendes, D.T. Covas, S. Kashima, A.M. Souza, F.A. Castro (University of São Paulo, Ribeirao Preto, Brazil) |
| 0322 | BOSUTINIB (SKI-606) COOPERATES WITH DASATINIB IN COUNTERACTING GROWTH AND VIABILITY OF CML CELLS CARRYING THE T315I MUTANT OF BCR/ABL K.V. Gleixner, L.L. Remsing Rix, U. Rix, R.A. Meyer, H. Herrmann, K. Schuch, W.F. Pickl, C. Sillaber, M. Augustin, J.H. Till, G. Superti-Furga, P. Valent (Medical University of Vienna, Vienna, Austria) |
| 0323 | EFFECT OF IMATINIB MESYLATE ON SERUM SOLUBLE VASCULAR ENDOTHELIAL GROWTH RECEPTOR-R2 AND MICROVESSEL DENSITY IN BCR-ABL POSITIVE CHRONIC MYELOID LEUKEMIA S.U. Mogalluru, P. Pati, S. Saxena (Kokilaben Dhirubhai Ambani Hospital, Mumbai, India) |
| 0324 | EXPRESSION LEVELS OF MIR-150 AND TRANSCRIPTION FACTORS PU., EGR2 INVERSELY CORRELATE WITH MYB AND MYCN IN CHRONIC MYELOID LEUKEMIA T. Lopotova, K. Vlcanova, T. Stopka, J. Moravcova, H. Klamova, K. Machova Polakova (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) |
| 0325 | PREDICTED COMBINATORIAL APPROACHES FOR OVERCOMING INTRINSIC IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA IDENTIFY POTENTIAL TARGETS FOR INTERVENTION S. Brems, W. Seifarth, D.B. Jackson, M. Giehl, A. Fabarius, M.A. Stein, R. Hehlmann, A. Hochhaus, O. Frank (Universitätsmedizin Mannheim, Mannheim, Germany) |
| 0326 | CCN, A NOVEL PRO-APOPTOTIC FACTOR FOR CHRONIC MYELOID LEUKAEMIA M.R. McCallum, W Lu, S Price, N Planque, B Perbal, N Lazar, A.E Irvine (Queen's University Belfast, Belfast, United Kingdom) |
| 0327 | 3-DEAZANEPLANOCIN A (DZNEP) ACTIVITY AGAINST CD34+ LEUKAEMIA STEM CELLS S. Myssina, G. Jørgensen, Y. Yu, T. Holyoake (University of Gasgow, Glasgow, United Kingdom) |
| 0328 | A SET OF NEW GENES THAT MAY BE INVOLVED WITH THE PROCESS OF MODIFICATION OF GRANULOCYTIC CELLS IN CHRONIC MYELOID LEUKEMIA (CML) C. Couto Mascarenhas (University of Campinas, Campinas, Brazil) |
| 0329 | HETEROGENEOUS MECHANISMS AT THE BASIS OF 5'BCR/3'ABL FUSION GENE GENERATION IN CHRONIC MYELOID LEUKEMIA F. Albano, L. Anelli, A. Zagaria, N. Coccaro, A. Pannunzio, A. Russo Rossi, L. Vicari, F. Manodoro, V. Liso, M. Rocchi, G. Specchia (Department of Hematology, Bari, Italy) |
| 0330 | EVALUATION OF DSBS REPAIR IN IMATINIB RESISTANT CELL LINES R. Dinis, L. Gromicho, S. Martins, L. Laires, A. Rueff, S. Rodrigues (Centro de Investigação em Genética Molecular Humana (CIGMH) - FCM/UNL, Lisbon, Portugal) |
| 0331 | E T315I MUTATION CONFERS RESISTANCE AGAINST SMALL MOLECULES BY RESTORING THE ABL-KINASE ACTIVITY ACCOMPANIED BY TRANSPHOSPHORYLATION OF ENDOGENOUS BCR, EVEN IN LOSS-OF-FUNCTION MUTANTS OF BCR/ABL M. Ruthardt, M. Mian, M. Schüll, Z. Zhao, C. Oancea, T. Beissert, H. Serve, O.G. Ottmann, M. Ruthardt (Goethe University, Frankfurt, Germany) |
| 0332 | SURVIVIN EXPRESSION IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH IMATINIBE MESYLATE TREATMENT M. Mantzourani, D. Georgopoulou, M. Gravia, A. Polonyfi, G. Pangalis, G. Vaiopoulos (National and Kapodistrian University of Athens, Goudi, Athens, Greece) |
| 0333 | AN APPROACH TO OVERCOME BCR-ABL INDEPENDENT STI571 RESISTANCE IN CML E. Rabizadeh, A. Aviram, I. Belyaeva, V. Merkin, N. Avissar, M. Shaklai, Y. Zimra (Beilinson, Petah Tikva, Israel) |
CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY I
| 0335 | DELTA EX, THE NOVEL TRANSACTIVATION-DEFECTIVE SPLICING VARIANT OF TP, IS DIFFERENTIALLY EXPRESSED IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND CONFERS ACCENTED PROLIFERATIVE PHENOTYPE IN VITRO |
|---|---|
| 0336 | THE TUMOR SUPPRESSOR MECHANISM IN 13Q14.3 INVOLVES MONOALLELIC EXPRESSION, NON-CODING RNA GENES AND EPIMUTATIONS AFFECTING THE MAJORITY OF CLL PATIENTS |
| 0337 | INTEGRATIVE HIGH-RESOLUTION MICROARRAYS APPROACH IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS THE PRESENCE OF MOLECULARLY DISTINCT SUBGROUPS IN PATIENTS WITH 13Q DELETION |
| 0338 | PROTEIN KINASE C INHIBITION WITH ENZASTAURIN PRIMES CHRONIC LYMPHOCYTIC LEUKEMIA CELLS FOR DEATH THROUGH DOWN-REGULATION OF MCL-1 |
| 0339 | ROLE OF CD38 IN HOMING OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS T. Vaisitti, S. Aydin, D. Rossi, L. Bergui, G. D'Arena, L. Bonello, G. Chiorino, G. Gaidano, F. Malavasi, S. Deaglio (Lab of Immunogenetics, Turin, Italy) |
| 0340 | THE FREQUENCY OF CIRCULATING CLL-LIKE B-CELL CLONES IN OTHERWISE HEALTHY INDIVIDUALS SIGNIFICANTLY INCREASES USING A HIGH-SENSITIVE MULTICOLOR FLOW CYTOMETRY APPROACH W. Nieto, M. Almeida, A. Romero, C. Teodosio, A. Lopez, A. Henriques, M.L. Sanchez, M. Jara, A. Rasillo, P. Fernandez-Navarro, T. Vega, A. Orfao (University of Salamanca, Salamanca, Spain) |
| 0341 | THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN(IG) VH GENES M. Coscia, F. Pantaleoni, C. Riganti, M. Rigoni, S. Peola, C. Vitale, D. Drandi, M. Ladetto, A. Bosia, M. Boccadoro, M. Massaia (Divisione di Ematologia dell'Università di Torino, Turin, Italy) |
| 0342 | GENOME-WIDE DNA COPY NUMBER ANALYSIS BY SNP ARRAYS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS THE PRESENCE OF NOVEL MOLECULAR LESIONS L. Mosca, L. Agnelli, S. Fabris, G. Cutrona, S. Matis, M. Lionetti, K. Todoerti, A. Andronache, M. Gentile, M. Spriano, V. Callea, G. Festini, S. Molica, G. Lambertenghi Deliliers, F. Morabito, M. Ferrarini, A. Neri (Università di Milano e Fondazione IRCCS Policlinico di Milano, Milan, Italy) |
| 0343 | THE SYK INHIBITOR R406 BLOCKS BCR SIGNALING, CELL ADHESION AND MIGRATION, AND INDUCES APOPTOSIS IN CLL CELLS: AN EXPLANATION FOR THE CLINICAL ACTIVITY OF R406 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) J.A. Burger, M.P. Quiroga, K. Balakrishnan, V. Gandhi, A. Kurtova, W.G. Wierda, M.J. Keating (The University of Texas MD Anderson Cancer Center, Houston, USA) |
| 0344 | MICRORNAS EXPRESSION PATTERN IN AGGRESSIVE SUBTYPE OF CHRONIC LYMPHOCYTIC LEUKEMIA M. Mraz, K. Malinova, J. Kotaskova, S. Pavlova, B. Tichy, J. Malcikova, J. Lochmanova, Y. Brychtova, M. Trbusek, J. Mayer, S. Pospisilova (Center of Molecular Biology and Gene Therapy,Dept.of Internal Med-Hematooncology, Brno, Czech Republic) |
| 0345 | IDENTIFICATION OF NOVEL RECURRENT COPY NUMBER VARIATIONS BY HIGH RESOLUTION COMPARATIVE GENOME HYBRIDISATION A.H. Schuh, S.J.L. Knight, E. SadighiAkha, T. Enver, J. Taylor (University of Oxford, Oxford, United Kingdom) |
| 0346 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTS VIA AUTO- AND PARACRINE MECHANISMS AS A CRITICAL MICROENVIRONMENTAL FACTOR FOR THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS I. Gehrke, J. Paesler, R.K. Gandhirajan, R. Razavi, M. Hallek, K.-A. Kreuzer (University Hospital Cologne, Cologne, Germany) |
| 0347 | LUMILIXIMAB INDUCES APOPTOSIS IN DRUG RESISTANT LYMPHOMA AND LEUKEMIA CELLS N. Pathan, S. Harris, S. Tangri, S. Hughes (Biogen Idec Inc, San Diego, USA) |
| 0348 | HIGH-RESOLUTION MICROARRAY CHARACTERIZATION OF THE 13Q14 DELETION EXTENT IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: CORRELATION WITH COPY NUMBER AND EXPRESSION LEVELS OF MIR-15A/16-1 CLUSTER L. Mosca, M. Lionetti, S. Fabris, G. Cutrona, L. Agnelli, G. Ciceri, S. Leone, V. Polli, S. Matis, M. Gentile, M. Spriano, V. Callea, G. Festini, S. Molica, G. Lambertenghi Deliliers, F. Morabito, M. Ferrarini, A. Neri (Università di Milano e Fondazione IRCCS Policlinico di Milano, Milan, Italy) |
CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS CLINICAL I
| 0349 | MICRORNA-29C AND 223 AND THEIR PROGNOSTIC VALUE IN CHRONIC LYMPHOCYTIC LEUKEMIA |
|---|---|
| 0350 | PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF ABT-263 IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) |
| 0351 | RESULTS OF THE PHASE II NCRI CLL206 TRIAL OF ALEMTUZUMAB IN COMBINATION WITH HIGH-DOSE METHYLPREDNISOLONE FOR HIGH-RISK (7P-) CLL |
| 0352 | STEROTYPED B-CELL RECEPTOR AND IGHV4-39 USAGE REPRESENT INDEPENDENT RISK FACTORS OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME |
| 0353 | FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY A. Egle, T Melchardt, L Pleyer, I Tinhofer, A. Lang, F. Keil, J. Thaler, E. Gunsilius, M. Fridrik, R. Greil (University Hospital Salzburg, Salzburg, Austria) |
| 0354 | LARGE BUT NOT SMALL COPY-NUMBER ALTERATIONS CORRELATE TO HIGH-RISK GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA: A HIGH-RESOLUTION GENOMIC SCREENING IN NEWLY DIAGNOSED PATIENTS R. Gunnarsson, A. Isaksson, M. Mansouri, H. Göransson, M. Jansson, N. Cahill, M. Rasmussen, J. Staaf, J. Lundin, S. Norin, A.M. Buhl, K. Ekström Smedby, H. Hjalgrim, K. Karlsson, J. Jurlander, G. Juliusson, R. Rosenquist (Stem Cell Center, Lund, Sweden) |
| 0355 | BENDAMUSTINE VERSUS CHLORAMBUCIL IN TREATMENTNAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED RESULTS OF AN INTERNATIONAL PHASE III STUDY U. Knauf, T. Lissichkov, A. Aldoud, R. Herbrecht, A. Liberati, J. Loscertales, G. Juliusson, G. Postner, L. Gercheva, S. Goranov, M. Becker, K. Hoeffken, F. Huguet, R. Foa, K. Merkle, M. Montillo (Onkologische Gemeinschaftspraxis, Frankfurt, Germany) |
| 0356 | EXPRESSION OF MUTATED IGHV3-23 GENES HAS INDEPENDENT PROGNOSTIC RELEVANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA AND IDENTIFIES A DISEASE SUBSET WITH PECULIAR MOLECULAR AND BIOLOGICAL FEATURES R. Bomben, M. Dal-Bo, D. Benedetti, D. Capello, F. Forconi, R. Maffei, L. Laurenti, D. Marconi, D. Rossi, F. Bertoni, M.I. Del Principe, F. Luciano, E. Sozzi, A. Zucchetto, F.M. Rossi, P. Bulian, E. Zucca, M. Degan, D.G. Efremov, R. Marasca, G. Del Poeta, G. Gaidano, V. Gattei (Centro di Riferimento Oncologico, Aviano, Italy) |
| 0357 | 5-YEAR FOLLOW-UP OF HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY CLL IN PHASE 3 STUDY: SIGNIFICANT SURVIVAL BENEFIT WITH OBLIMERSEN PLUS FLUDARABINE/ CYCLOPHOSPHAMIDE IN RESPONDING PATIENTS M. O’Brien, J. Gribben, T. Cousin, K. Rai (The University of Texas M.D. Anderson Cancer Center, Houston, USA) |
| 0358 | CD49D EXPRESSION AND SHORT TELOMERE LENGTH INTERACT IN CHRONIC LYMPHOCYTIC LEUKEMIA AND IDENTIFY PATIENTS AT RISK OF PROGRESSION AND SHORT SURVIVAL D. Rossi, M. Ladetto, C. Lobetti Bodoni, A. Zucchetto, F.M. Rossi, V. Gattei, G. Gaidano (Division of Hematology, Amedeo Avogadro University, Novara, Italy) |
| 0359 | UPDATE OF THE FRENCH LGL PROLIFERATION REGISTRY: REPORT OF 229 CASES T. Lamy, B. Bareau, J. Rey, M. Hamidou, J. Donadieu, O. Reman, N. Schleinitz, O. Tournilhac (University Hospital, Rennes, France) |
| 0360 | MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) IN FIRST-DEGREE RELATIVES OF PATIENTS WITH SPORADIC (NON-FAMILIAL) CHRONIC LYMPHOCYTIC LEUKEMIA D. Matos, S.J. Ismael, C.A. Scrideli, F.O. Morato, R.P. Falcão (University Hospital of Ribeirão Preto (USP), Ribeirao Preto-SP, Brazil) |
| 0361 | NCRN CLL207 STUDY OF ALEMTUZUMAB CONSOLIDATION IN CLL: REPORT OF THE PLANNED INTERIM ANALYSIS P. Hillmen, D.R. Cohen, C. Dearden, G. Follows, W.M. Gregory, A.F. Smith, E.J. Skinner, A. Critchley, A.C. Rawstron, C.D. Fegan, H. McCarthy, C.F. Pocock (Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom) |
| 0362 | NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS M. Doubek, E. Cmunt, J. Schwarz, M. Brejcha, Z. Pospisil, P. Kozmon, Y. Brychtova, S. Pospisilova, P. Cetkovsky, M. Trneny, J. Mayer (University Hospital, Brno, Czech Republic) |
| 0363 | LENALIDOMIDE INDUCED UPREGULATION OF CD80 ON LEUKEMIC CELLS CORRELATES WITH T-CELL ACTIVATION, THE RAPID ONSET OF A CYTOKINE RELEASE SYNDROME AND CLEARANCE OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA A. Wiestner, N Njuguna, B Vire, P McCoy Jr, W Wilson, S Pittaluga, G Aue (HB, NHLBI, NIH, Bethesda, USA) |
| 0364 | STANDARD AND REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS (HSCT) FROM RELATED AND UNRELATED DONORS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). A LONG-TERM FOLLOW-UP (0 YEARS) STUDY FROM THE EBMT REGISTRY M. Michallet, Q.-H. Le, P. Dreger, M. Sobh, D. Niederwieser, V. Koza, T. Ruutu, N. Russell, L. Verdonck, D. Milligan, N. Dhedin, T. Kozak, M. Boogaerts, J. Finke, A. van Biezen, R. Brand, T. de Witte (Edouard Herriot Hospital, Lyon, France) |
| 0365 | INCREASED EXPRESSION OF MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA ON TREPHINE BIOPSIES CORRELATES WITH ADVANCED MYELOMA, EXTENSIVE BONE DISEASE AND ELEVATED MICROVESSEL DENSITY IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA E. Terpos, A. Tasidou, M. Roussou, E. Kastritis, M. Migkou, D. Christoulas, M. Gavriatopoulou, F. Zagouri, C. Matsouka, T. Papadaki, M.A. Dimopoulos (University of Athens School of Medicine, Athens, Greece) |
| 0366 | SECRETOME ANALYSES OF PRIMARY BONE MARROW FIBROBLASTS ISOLATED FROM MGUS AND MULTIPLE MYELOMA PATIENTS SUPPORT THE ROLE OF THE MICROENVIRONMENT FOR MYELOMA PATHOGENESIS J. Drach, A. Slany, T. Mohr, J. Griss, J. Ackermann, C. Zielinski, C. Gerner (Medical University of Vienna, Vienna, Austria) |
| 0367 | MICRORNAS AS KEY REGULATORS OF MULTIPLE MYELOMA CELL GROWTH M. Roccaro, A. Sacco, A.K. Azab, X. Leleu, B.D. Thompson, F. Azab, X. Jia, H.T. Ngo, J. Runnels, M.R. Melhem, K.C. Anderson, T. Witzig, I.M. Ghobrial (Dana-Farber Cancer Institute, Boston, USA) |
| 0368 | LENALIDOMIDE INDUCED P27 KIP1-ASSOCIATED GROWTH ARREST IN MYELOMA CELLS THROUGH DOWN-REGULATION OF BOTH C-MYC AND SCFSKP2 UBIQUITIN LIGASE M. Amiot, S. Bonnaud, S. Maiga, G. Descamps, C. Pellat-Deceunynck, R. Bataille (Inserm U8, Nantes, France) |
| 0369 | THE MTOR PATHWAY ACTIVATION PREDICTS A SHORT TIME TO PROGRESSION AND OVERALL SURVIVAL IN RELAPSED MULTIPLE MYELOMA PATIENTS T. Guglielmelli, R. Merlini, E. Giugliano, G. Saglio, V. Brunetto, S. Cappia, E. Bacillo, A. Berruti, F. Gay, M. Papotti, A. Palumbo (AUO San Luigi Gonzaga, Orbassano, Italy) |
| 0370 | ANTIBODY RESPONSES TO CANCER-TESTIS ANTIGENS IN MULTIPLE MYELOMA PATIENTS M.D. Kobold, Y. Cao, S. Tams, B.M. Bartels, C. Eberhardt, M. Ristic, T. Lütkens, C. Pabst, C. Bokemeyer, N. Kröger, D. Atanackovic (University medical center Hamburg-Eppendorf, Hamburg, Germany) |
| 0371 | A NOVEL FISH-BASED NORMALIZATION PROCEDURE FOR WHOLE GENOME MICROARRAYS DETECTING ACCURATE LOCAL COPY NUMBERS: APPLICATION TO MULTIPLE MYELOMA L. Agnelli, L. Mosca, A. Andronache, S. Fabris, M. Lionetti, I. Kwee, K. Todoerti, D. Verdelli, L. Nobili, V. Polli, C. Battaglia, F. Bertoni, G. Lambertenghi Deliliers, A. Neri (University of Milan and Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy) |
| 0373 | CARFILZOMIB: A SELECTIVE INHIBITOR OF THE CHYMOTRYPSINLIKE ACTIVITY OF THE CONSTITUTIVE PROTESOME AND IMMUNOPROTEASOME HAS ANTI-TUMOR ACTIVITY ON MULTIPLE MYELOMA, LYMPHOMA AND LEUKEMIA CELLS WITH MINIMAL EFFECTS ON NORMAL CELLS F. Parlati, S. Lee, M. Aujay, K. Levitsky, J. Lorens, Y. Lu, D. Micklem, P. Rurrs, K. Shenk, C. Sun, E. Suzuki, C. Sylvain, M.K. Bennett (Proteolix, South San Francisco, USA) |
| 0374 | CORRELATIONS BETWEEN ANGIOGENESIS, MIP-1 ALPHA EXPRESSION BY MALIGNANT CELLS AND MACROPHAGE COUNTS IN WALDENSTROM'S MACROGLOBULINEMIA: IMPLICATIONS INTO THE BIOLOGY OF THE DISEASE E. Terpos, A. Tasidou, E. Eleutherakis-Papaiakovou, D. Christoulas, M. Gavriatopoulou, M. Migkou, E. Kastritis, T. Papadaki, M.A. Dimopoulos (University of Athens School of Medicine, Athens, Greece) |
| 0375 | ABNORMAL SERUM FREE-LIGHT CHAIN RATIO IN PATIENTS WITH MULTIPLE MYELOMA IN LONG-LASTING COMPLETE REMISSION: STRONG ASSOCIATION WITH OLIGOCLONAL BANDS C. Fernández de Larrea, M.T. Cibeira, M. Elena, L. Rosiñol, M. Rovira, J.J. Arostegui, X. Filella, J. Yagüe, J. Bladé (Hospital Clínic de Barcelona, Barcelona, Spain) |
| 0376 | DASATINIB ENHANCED APOPTOSIS OF RAPAMYCIN IN MULTIPLE MYELOMA CELLS THROUGH DOWN-REGULATION OF THE MTOR PATHWAY BY ABROGATING SIGNALING VIA AKT AND ERK T. Guglielmelli, E. Giugliano, R. Merlini, M. Pautasso, I. Defilippi, S. Mussino, V. Brunetto, E. Bracco, G. Saglio (AUO San Luigi Gonzaga, Orbassano, Italy) |
| 0377 | PTEN IS DOWN REGULATED IN MULTIPLE MYELOMA G. Piras, M. Monne, L. Pilo, A. Calvisi, A. Uras, M. Murineddu, L. Arca, L. Arru, L. Curreli, G.C. Latte, A. Murgia, A. Gabbas (U.O. Hematology, Nuoro, Italy) |
| 0378 | DIFFUSE MRI PATTERN CORRELATES WITH INCREASED ANGIOGENESIS, EXTENSIVE BONE DISEASE AND POOR PROGNOSIS IN NEWLY-DIAGNOSED, PRIOR-UNTREATED, PATIENTS WITH MULTIPLE MYELOMA E. Terpos, M.A. Dimopoulos, D. Christoulas, E. Kastritis, A. Koureas, M. Roussou, M. Gavriatopoulou, M. Migkou, M. Iakovaki, M. Gotzamanidou, A. Tasidou, L.A. Moulopoulos (University of Athens School of Medicine, Athens, Greece) E. Terpos, M.A. Dimopoulos, D. Christoulas, E. Kastritis, A. Koureas, M. Roussou, M. Gavriatopoulou, M. Migkou, M. Iakovaki, M. Gotzamanidou, A. Tasidou, L.A. Moulopoulos (University of Athens School of Medicine, Athens, Greece) |
| 0379 | CORRELATION BETWEEN LOSSES OF THE IGH OR ITS SEGMENTS AND DELETIONS OF 13Q14 IN MULTIPLE MYELOMA WITH TRANSLOCATION T(1;14) (Q13;Q32) DETECTED BY COMBINED ANALYSIS OF MORPHOLOGY AND FISH L. Trakhtenbrot, I. Hardan, M. Koren-Michowitz, Sh. Oren, G. Yeshoev, G. Rechavi, A. Nagler, N. Amariglio (Institute of Hematology, Ramat Gan, Israel) |
| 0380 | BUSULPHAN PLUS MELPHALAN (BUMEL) VERSUS MELPHALAN- 200 MG (MEL) AS CONDITIONING REGIMENS FOR MULTIPLE MYELOMA (MM): A SEQUENTIAL PROSPECTIVE COMPARATIVE STUDY OF EFFICACY AND TOXICITY J. Martínez, M.V. Mateos, M.V. Mateos, J. de la Rubia, L. Rosiñol, A. Sureda, J. García-Laraña, R. Martínez, M.T. Hernandez, D. Carrera, J. Besalduch, F. de Arriba, A. Oriol, L. Escoda, B. Hernández, J. Garcia-Frade, C. Rivas González, A. Alegre, J. Bladé, J. San Miguel, J.J. Lahuerta (Hospital 12 de Octubre, Madrid, Spain) |
| 0381 | TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY P.G. Richardson, A. Chanan-Khan, S. Lonial, A. Krishnan, M. Carroll, M. Alsina, M. Albitar, D. Berman, T. Szatrowski, S. Kaplita, K.C. Anderson (Dana-Farber Cancer Institute, Boston, USA) |
| 0382 | COMBINATION OF THALIDOMIDE, PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE AND BORTEZOMIB (THADD-V) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): RESULTS OF A PHASE II STUDY M. Offidani (Clinica di Ematologia Ospedali Riuniti Ancona, Ancona, Italy) |
| 0383 | A MULTICENTER PHASE II CLINICAL TRIAL OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA A. Palumbo, A. Larocca, G. Sanpaolo, A.P. Falcone, V. Federico, L. Canepa, M. Crugnola, V. Magarotto, F. Cavallo, M.T. Petrucci, M. Boccadoro (A.O.U. San Giovanni Battista, Turin, Italy) |
| 0384 | THALIDOMIDE-INTERFERON VS. INTERFERON MAINTENANCE THERAPY AFTER INDUCTION WITH THAL-DEX OR MP IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA H. Ludwig, Z. Adam, E. Tóthová, R. Hajek, B. Labar, M. Egyed,I. Spicka, J. Drach, H. Gisslinger, I. Kuhn, N. Zojer, A. Hinke (Wilhelminenspital, Vienna, Austria) |
| 0385 | REVERSAL OF ACUTE RENAL IMPAIRMENT BY BORTEZOMIBDOXORUBICIN- DEXAMETHASONE (BDD) IN MULTIPLE MYELOMA (MM). RESULTS FROM AN PHASE II STUDY H. Ludwig, Z. Adam, R. Greil, E. Tóthová, F. Keil, N. Zojer, J. Thaler, H. Gisslinger, M. Egyed, A. Lang (Wilhelminenspital, Vienna, Austria) |
| 0386 | THE PRESENCE OF RESIDUAL NORMAL PLASMA CELLS BY MULTIPARAMETER FLOW CYTOMETRY IN THE BONE MARROW OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS IDENTIFIES A GOOD PROGNOSTIC SUBGROUP B. Paiva, M. Vidriales, J. Cerveró, G. Mateo, J. Pérez, M.A. Montalbán, A. Sureda, L. Montejano, N. Gutiérrez, A. García de Coca, N. De las Heras, M. Mateos, M. López-Berges, R. García-Boyero, J. Galende, J. Hernández, L. Palomera, D. Carrera, R. Martínez, J. De la Rubia, A. Martín, J. Bladé, J. Lahuerta, A. Orfao, J.F. San Miguel (University Hospital of Salamanca, Salamanca, Spain) |
| 0387 | COMBINED VORINOSTAT, LENALIDOMIDE AND DEXAMETHASONE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE I STUDY D. Siegel, D. Weber, C. Mitsiades, M. Dimopoulos, J. Harousseau, S. Rizvi, J. Howe, D. Reiser, K. Anderson, P. Richardson (Hackensack University Medical Center, Hackensack, USA) |
| 0388 | SURVIVAL AND YEARS OF LIFE LOST IN DIFFERENT AGE CATEGORIES OF PTS WITH MM H. Ludwig, Z. Adam, E. Tóthová, R. Hajek, B. Labar, M. Egyed, I. Spicka, J. Drach, H. Gisslinger, I. Kuhn, N. Zojer, A. Hinke (Wilhelminenspital, Vienna, Austria) |
| 0389 | BORTEZOMIB , PEGYLATED LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE (B-D-D) AS THERAPY FOR ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: A WEEKLY BORTEZOMIB SCHEDULE REDUCES TOXICITIES MANTAINING THE SAME EFFICACY A. Gozzetti, A. Fabbri, E. Marchini, S. Oliva, M. Defina, M. Bocchia, F. Lauria (University of Siena, Siena, Italy) |
| 0390 | BETA-2 MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA D. Rossi, M. Fangzio, L. De Paoli, V. Pinto, P. Riccomagno, A. Puma, A. Ramponi, G. Gaidano (Division of Hematology, Amedeo Avogadro University, Novara, Italy) |
| 0391 | PATTERNS OF SURVIVAL AND CAUSES OF DEATH FOLLOWING A DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS): A POPULATION-BASED STUDY S.Y. Kristinsson, M. Björkholm, T.M.L. Andersson, S. Eloranta, P.W. Dickman, L.R. Goldin, C. Blimark, U.H. Mellqvist, A. Wahlin, I. Turesson, O. Landgren (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden) |
| 0392 | BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE OVERCOMES THE NEED FOR ADDITIONAL CHEMOTHERAPY PRIOR TO HIGH-DOSE THERAPY WITH AUTOTRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA A. Corso, L. Barbarano, S. Mangiacavalli, L. Montalbetti, A.M. Cafro, A.M. Carella, M. Spriano, P.E. Alessandrino, G. Grillo, M. Varettoni, P. Bernasconi, M. Lazzarino, E. Morra (Fondazione IRCCS Policlinico San Matteo, University of pavia, Pavia, Italy) |
| 0393 | SURVIVAL EFFECT OF ERYTHOPOIETIC AGENTS AND VENOUS THROMBOEMBOLISM (VTE) IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE AND HIGH-DOSE DEXAMETHASONE M. Zangari, G. Tricot, L. Polavaram, A. Finlayson, F. Zhan, R. Knight, T. Fu, D. Weber, M. Dimopoulos, R. Niesvizky, L. Fink (University of Utah, Salt Lake City, USA) |
| 0394 | SERUM DKK1 IN MULTIPLE MYELOMA PATIENTS U. Heider, M. Kaiser, M. Mieth, J. Rademacher, B. Lamottke, C. Jakob, E. Braendle, D. Stover, O. Sezer (Charite Campus Mitte, Berlin, Germany) |
| 0395 | LENALIDOMIDE-BASED THERAPY LEADS TO IMPROVEMENT OF HUMORAL IMMUNE SYSTEM IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS WHO RESPOND TO THE THERAPY R. Baz, M. Dimopoulos, P. Richardson, Z. Yu, M. Hussein, A. Chanan-Khan (Moffitt Cancer Center, Tampa, USA) |
| 0396 | UP-FRONT SALVAGE TREATMENT WITH MELPHALAN 100 MG/M2 IN FULMINANT PROGRESSION OF MULTIPLE MYELOMA AND CONSOLIDATION WITH NOVEL DRUGS M. Krejci, Z. Adam, A. Krivanova, L. Pour, M. Holanek, V. Sandecka, J. Mayer, J. Vorlicek, R. Hajek (University Hospital Brno, Brno, Czech Republic) |
| 0397 | SPEED OF RESPONSE WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FIRST RESULTS OF THE MM-019 GERMAN COMPASSIONATE USE PROTOCOL K.C. . Weisel, M. Hänel, D. Niederwieser, R. Naumann, N. Kröger, M. Engelhardt, H. Goldschmidt, N. Lang, C. Scheid, H.G. Sayer, A. Glasmacher, U. Dührsen (University of Tuebingen, Tuebingen, Germany) |
| 0398 | USE OF MAINTENANCE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE (VD) IN ADVANCED MULTIPLE MYELOMA G. Benevolo, A. Larocca, P. Pregno, F. Gay, B. Botto, C. Gentile, C. Frairia, A. Evangelista, F. Morabito, A. Palumbo, U. Vitolo, M. Boccadoro (Hematology, Turin, Italy) |
| 0399 | HALOFUGINONE, AN ORALLY-BIOAVAILABLE AGENT, HAS IN VITRO AND IN VIVO ANTIMYELOMA ACTIVITY, ASSOCIATED WITH UP REGULATION OF C-JUN, JNK, AND P-, PROAPOPTOTIC PROTEINS M. Leiba, J. Jakubikova, S. Klippel, C. Mitsiades, T. Hideshima, Y.T. Tai, P. Richardson, A. Nagler, K. Anderson (Dana Farber Cancer Institute, Boston, USA) |
| 0400 | SERUM LEVELS OF TOTAL-RANKL IN MULTIPLE MYELOMA A. Goerke, C. Jakob, J. Sterz, U. Heider, M. Kaiser, M. Mieth, C. Müller,E. Terpos, O. Sezer (Charité - Universitätsmedizin Berlin, Berlin, Germany) |
NON-HODGKIN LYMPHOMA - CLINICAL I
| 0401 | QUALITATIVE AND QUANTITATIVE ASSESSMENT OF BONE MARROW INVOLVEMENT IN THE ENTIRE SPECTRUM OF NONHODGKIN'S LYMPHOMAS: COMPARISON BETWEEN HISTOLOGY AND FLOW CYTOMETRY IN 572 PATIENTS |
|---|---|
| 0402 | CLIPI: A NEW PROGNOSTIC INDEX FOR INDOLENT CUTANEOUS B-CELL LYMPHOMA PROPOSED BY THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG 11) |
| 0403 | RITUXIMAB-CHOP (R-CHOP) IN THE TREATMENT OF 441 DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS: OUTCOME AND PROGNOSTIC FACTORS FOCUSING TO THE REVISED INTERNATIONAL PROGNOSTIC INDEX (R-IPI) |
| 0404 | FINAL RESULTS OF THE PHASE II MULTICENTER ITALIAN STUDY OF IMMUNOCHEMOTHERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) FOR SYMPTOMATIC WALDENSTROM'S MACROGLOBULINEMIA |
| 0405 | LNH-PRO-05 STUDY: EXCELLENT CLINICAL AND MOLECULAR RESPONSES IN FLIPI=2 FOLLICULAR LYMPHOMA PATIENTS WITH RITUXIMAB PLUS CVP (BAGLEY) AND 12 WEEKS OF INTERFERON ALFA J. Cannata-Ortiz, C. Nicolás, A. Garcia-Noblejas, S. Montes-Moreno, J. López, M.J. Requena, M.A. Piris, R. Arranz (Hospital de la Princesa, Madrid, Spain) |
| 0406 | POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD): CHARACTERISTICS AND OUTCOME IN A BELGIAN UNIVERSITY HOSPITAL D. Dierickx, T. Tousseyn, C. De Wolf-Peeters, M. Delforge, T. Devos, A. Janssens, J. Maertens, S. Meers, G. Verhoef (University Hospitals Gatshuisberg, Leuven, Belgium) |
| 0407 | SAFETY AND CLINICAL ACTIVITY OF THE ANTI-CD22 IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) IN COMBINATION WITH RITUXIMAB IN RECURRENT/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA W.M. Johnson, L.E. Fayad, B. Coiffier, M.D. Smith, A. Rohatiner, G. Hess, J.L. Kaufman, G. Verhoef, F. Offner, S. Hua, H. Patel, E.R. Vandendries, N.H. Dang (CR UK Centre, Southampton, United Kingdom) |
| 0408 | CLINICAL SIGNIFICANCE OF THE PRESENCE OF OCCULT CNS INVOLVEMENT ASSESSED BY FLOW CYTOMETRY IN PATIENTS WITH NON HODGKIN'S LYMPHOMA AT HIGH RISK OF CNS RELAPSE J.M. Sancho, A. Orfao, S. Quijano, O. Garcia, C. Panizo, E. Pérez-Ceballos, G. Deben, A. Salar, E. González-Barca, N. Alonso, J.A. García-Vela, J. Capote, F.J. Peñalver, M. Provencio, J. Arias, J. Plaza, D. Caballero, M. Morado, M. Cruz, A. Palacios, A. Carmona, E. Conde, T. Molero, E. Romero, M.C. Mateos, M.J. Peñarrubia, J.M. Ribera (ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain) |
| 0409 | A PHASE 2 STUDY OF VORINOSTAT (SUBEROYLANILIDE HYDROXAMIC ACID, SAHA) IN RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA. A CALIFORNIA CANCER CONSORTIUM STUDY M. Kirschbaum, L. Popplewell, A. Nademanee, V. Pullarkat, M. Delioukina, J. Zain, D. Matsuoka, B. Pulone, P. Frankel, S. Forman, I. Espinoza-Delgado, E. Newman (City of Hope National Cancer Center, Duarte, USA) |
| 0410 | EARLY EVALUATION OF 18-FDG-POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET) DOES NOT PREDICT THE OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS TREATED WITH R-CHOP P. Pregno, A. Chiappella, M. Bellò, S. Ferrero, R. Passera, C. Boccomini, B. Botto, G. Castellano, C. Frairia, S. Franceschetti, R. Freilone, M. Menga, F. Salvi, M. Ladetto, U. Vitolo (Hematology , AOU San Giovanni Battista, Turin, Italy) |
| 0411 | ACTIVITY AND SAFETY OF BORTEZOMIB AND RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT NON FOLLICULAR AND MANTLE-CELL NON HODGKIN LYMPHOMA: A PHASE II MULTICENTER STUDY BY INTERGRUPPO ITALIANO LINFOMI P. Pregno, A. Chiappella, P.L. Zinzani, L. Orsucci, V. Stefoni, E. Russo, A. Tucci, S. Franceschetti, R. Freilone, A. Fabbri, A. Ferreri, L. Gargantini, A.M. Liberati, L. Rigacci, A. Evangelista, U. Vitolo (On behalf of Intergruppo Italiano Linfomi, Hematology , AOU S.Giovanni Battista, Turin, Italy) |
| 0412 | LYMPHOMA - EMERGING REALITIES IN SUB-SAHARA AFRICA P. Jacobs, G. Sissolak, J. Juritz, D. Sissolak, L. Wood (Stellenbosch University, Cape Town, South Africa) |
| 0413 | FIRST RESULTS OF LONG TERM RITUXIMAB MAINTENANCE TREATMENT IN FOLLICULAR LYMPHOMA: SAFETY ANALYSIS OF THE RANDOMIZED PHASE III TRIAL SAKK 35/03 F. Hitz, S. Bassi, C. Taverna, W. Mingrone, T. Pabst, L. Cevreska, A. Del Giglio,D.A. Vorobiof, M. Simcock, M. Ghielmini (Kantonsspital St. Gallen, St. Gallen, Switzerland) |
| 0414 | VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA F. Mendicino, L. Marcheselli, A . Bari, R. Marcheselli, S. Falorio, G. Polimeno, M.C. Cox (A.O. Sant'Andrea - 2nd Faculty of Medicine - “La Sapienza” University, Rome, Italy) |
| 0415 | SPLENECTOMY VERSUS RITUXIMAB IN THE TREATMENT OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) C. Kalpadakis, G.A. Pangalis, T.P. Vassilakopoulos, S. Sachanas, M.C. Kyrtsonis, M. Dimopoulou, P. Korkolopoulou, F.N. Kontopidou, X. Yiakoumis, M.P. Siakantaris, E.M. Dimitriadou, P. Panayiotidis, H. Papadaki, M.K. Angelopoulou (Department of Haematology, University of Crete, Athens, Greece) |
| 0416 | PHASE II STUDY OF INTRATHECAL LONG ACTING LIPOSOMAL CYTARABINE (DEPOCYTE_) IN THE PROPHYLAXIS OF LYMPHOMATOUS MENINGITIS IN HIV-RELATED NON-HODGKIN'S LYMPHOMA M. Spina, E. Chimienti, F. Martellotta, M. Berretta, E. Zanet, P.K. Nigri, V. Canzonieri, P. Bulian, U. Tirelli (National Cancer Institute, Aviano, Italy) |
| 0417 | INTEREST OF 18-FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN INITIAL STAGING, RESPONSE ASSESSMENT AND PROGNOSTIC VALUE OF MANTLE CELL LYMPHOMA (MCL) C. Touzeau, C. Bodet-Milin, C. Leux, S. Mehmet, A. Moreau, H. Maisonneuve, N. Morineau, H. Jardel, P. Moreau, R. Gressin, J.L. Harousseau, P. Moreau, F. Kraeber-Bodere, S. Le Gouill (University Hospital, Nantes, France) |
| 0418 | LONG-TERM FOLLOW-UP OF RITUXIMAB AND INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE (CDE) IN COMBINATION WITH HAART IN HIV-RELATED NON-HODGKIN'S LYMPHOMAS (NHL) M. Spina, E. Chimienti, E. Vaccher, U. Jaeger, J.A. Sparano, R. Talamini, U. Tirelli (National Cancer Institute, Aviano, Italy) |
NON-HODGKIN LYMPHOMA - CLINICAL II
| 0419 | HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA INTO DIFFUSE LARGE B-CELL LYMPHOMA IN THE IOSI EXPERIENCE |
|---|---|
| 0420 | FOLLICULAR LYMPHOMA IN LEUKEMIC PHASE AT DIAGNOSIS: CLINICAL AND BIOLOGICAL FEATURES IN A SERIES OF 24 PATIENTS AND COMPARATIVE ANALYSIS WITH NON-LEUKEMIC PATIENTS |
| 0421 | ORAL VORINOSTAT COMBINED WITH BEXAROTENE IN ADVANCED CUTANEOUS T-CELL LYMPHOMA: A PHASE I STUDY |
| 0422 | CLINICAL IMPACT OF SIX-COLOR FLOW CYTOMETRY IN LYMPHOPROLIFERATIVE DISORDERS: IDENTIFICATION AND EXTENDED CHARACTERIZATION OF COMPOSITE LYMPHOMAS |
| 0423 | LONG-TERM FOLLOW-UP OF TANDEM HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR ADULTS WITH HIGH-RISK AGE-ADJUSTED INTERNATIONAL PROGNOSTIC INDEX AGGRESSIVE NON-HODGKIN'S LYMPHOMAS: A GOELAMS PILOT STUDY H. Monjanel, E. Deconinck, E. Perrodeau, B. Mahé, V. Delwail, A. Moreau, S. François, C. Berthou, E. Gyan, N. Milpied (CHU de Tours, Hopital Bretonneau, Tours, France) |
| 0424 | RAPID INFUSION OF RITUXIMAB IS WELL TOLERATED AND ENABLES MORE EFFICIENT USE OF HAEMATOLOGY DAY WARD RESOURCES S. Peinert, M. Moloney, H.M. Prince, M. Wolf, D. Ritchie, D. Westerman, D. Carney, H. Januszewicz, K. Herbert, S. Harrison, J.F. Seymour (Peter MacCallum Cancer Centre, Melbourne, Australia) |
| 0425 | A NOVEL GERMLINE MUTATION IN MSH6 - IMPLICATIONS FOR THE CLINICAL CARE OF CHILDHOOD LEUKAEMIA/LYMPHOMA PATIENTS T. Ripperger, C. Beger, N. Rahner, K.W. Sykora, C. Bockmeyer, U. Lehmann, H.H. Kreipe, B. Schlegelberger (Hannover Medical School, Hannover, Germany) |
| 0426 | DOSE-DENSE THERAPY WITH NON-PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE AND RITUXIMAB (R-COMP) IS FEASIBLE AND EFFECTIVE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: R-COMP 14 VS R-COMP 21. INTERIM ANALYSIS FROM AN ITALIAN MULTICENTE G. Visani, F. Ferrara, F. Merli, F. Angrilli, F. Ilariucci, S. Falorio, G. Fioritoni, F. Alesiani, M. Brunori, F. Pollio, M. Celentano, D. Cangini, S. Ronconi, M. Catarini, G. Giglio, D. Vallisa, A. Arcari, D. Bernardi, B. Guiducci, S. Barulli, F. Loscocco, A. Isidori (Department of Hematology, Pesaro, Italy) |
| 0427 | ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA PATIENTS WHO PROGRESSED AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY BASED ON DONOR AVAILABILITY J.W. Kim, B.S. Kim, S.M. Bang, I. Kim, S.S. Yoon, J.S. Lee, K.S. Han, S. Park, B.K. Kim (Seoul National University Hospital, Seoul, South-Korea) |
| 0428 | IFOSFAMIDE, EPIRRUBICIN, AND ETOPOSIDE (IEV) AS MOBILIZATION-THERAPY REGIMEN FOR PATIENTS WITH NONHODGKIN LYMPHOMA AND HODGKIN DISEASE: COMPARISON WITH OTHER CHEMOTHERAPY REGIMENS L. Quintana-Paris, J.M. Bergua, J. Sanchez-Garcia, J. Serrano, H. Bañas, M.A. Alvarez, J. Prieto-Fernandez, G. Rodriguez-Garcia, M. Bengochea-Casado, A. Torres-Gomez (University Hospital Reina Sofia, Cordoba, Spain) |
| 0429 | SMALL LYMPHOCYTIC LYMPHOMA (SLL): RETROSPECTIVE ANALYSIS FROM THE REGISTRY OF CZECH LYMPHOMA STUDY GROUP L. Smolej, I. Vasova, J. Salkova, D. Belada, A. Sykorova, M. Jankovska, V. Campr, H. Krejcova, M. Trneny (University Hospital and Medical School, Hradec Kralove, Czech Republic) |
| 0430 | PHARMACODYNAMIC ANALYSES OF PERIPHERAL BLOOD FROM RELAPSED B-NHL PATIENTS TREATED WITH ANTI-CD19/-CD3 BISPECIFIC BITE_ ANTIBODY BLINATUMOMAB M. Klinger, D. Nagorsen, C. Brandl, S. Wissing, P. Meier, P.A. Baeuerle, P. Kufer (Micromet AG, Munich, Germany) |
| 0431 | SAFETY AND EFFICACY OF BENDAMUSTINE WITH OR WITHOUT RITUXIMAB IN THE TREATMENT OF HEAVILY PRETREATED PATIENTS WITH LYMPHOMA OR CLL. A MULTICENTER RETROSPECTIVE STUDY L. Rigacci, B. Puccini, A. D'Arco, E. Orciuolo, S. Cortelazzo, G. Gaidano, C. Patti, P. Musto, P.L. Zinzani, S. Storti, A. Carpaneto, N. Di Renzo, N. Cascavilla, V. Belsito Petrizzi, N. Cecconi, G. Buda, S. Franceschetti, E. Derenzini, A. Costa, G. Giordano, M. Montanaro, A. Billio, G. Mansueto, A. Bosi (Azienda Ospedaliera Careggi, Florence, Italy) |
| 0432 | CONTINUOUS, ORAL CYCLOPHOSPHAMIDE AND PREDNISOLONE AS A VALID TREATMENT OPTION FOR PERIPHERAL T CELL LYMPHOMA A. Tucci, E. Cerqui, M. Ungari, S. Ferrari, A. Bacigalupo, F. Facchetti, G. Rossi (Spedali Civili, Brescia, Italy) |
| 0433 | LONG TERM OUTCOME OF HIGH DOSE ARACYTINE, RITUXIMAB, AND DEXAMETHASONE CHEMOTHERAPY FOR AGGRESSIVE MANTLE CELL LYMPHOMA IN ELDERLY PATIENTS R. KOTB, J.A. Boisjoly, P. Beauregard, M. Lepine-Martin (CHU de Sherbrooke, Sherbrooke, Canada) |
| 0434 | DOSE INTENSITY IN HODGKIN AND NON-HODGKIN'S LYMPHOMA J.M. Mariz, A. Teixeira, A. Marques Pereira, J. Espírito Santo, M. Marques, E. Magalhães, C. Portela, M.C. Trindade, R. Costa, I. Oliveira, R. Vieira, H. Marques (Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., Porto, Portugal) |
| 0436 | THE NEW ALC/R-IPI SCORE HAS A GOOD ABILITY TO DISCRIMINATE PROGNOSIS IN DLBCL TREATED WITH IMMUNO-CHEMOTHERAPY M. Cox, I. Nofroni, L. Ruco, R. Amodeo, B. Veggia, A. Ferrari, G. La Verde, P. Cardelli, E. Montefusco, E. Conte, G. Antolino, M.P. Bianchi, B. Monarca, M.A. Aloe spirit (A.O. Sant'Andrea, Rome, Italy) |
THROMBOSIS AND VASCULAR BIOLOGY I
| 0437 | PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY: THE ADVANTAGE OF FIXED SUBTHERAPEUTIC DOSES OF LOW-MOLECULAR WEIGHT HEPARIN |
|---|---|
| 0438 | RESISTANCE TO CLOPIDOGREL DETECTED BY REAL TIME EVALUATION OF PLATELET THROMBUS FORMATION |
| 0439 | EFFECT OF THE NOVEL, ORAL, DIRECT FACTOR XA INHIBITOR RIVAROXABAN ON COAGULATION ASSAYS |
| 0440 | THE HEMOSTATIC PROFILE OF ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS IS INFLUENCED BY THE JAK2V617F ALLELE BURDEN |
| 0441 | SOLUBLE ENDOGLIN AND ITS INTERACTION WITH ADHESION MOLECULES IN PATIENTS WITH THALASSEMIA INTERMEDIA I. Papassotiriou, M. Siopi, C. Lazaropoulou, I. Kanavaki, V. Ladis, A. Kattamis (Aghia Sophia Childen's Hospital, Athens, Greece) |
| 0442 | ORAL PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT SURGERY IN THE ELDERLYAND THOSE WITH MODERATE RENAL IMPAIRMENT: EFFICACY AND SAFETY PROFILE OF DABIGATRAN ETEXILATE O.E. Dahl, A.A. Kurth, N. Rosencher, A. Clemens, M. Feuring, H. Noack, B.I. Eriksson (Thrombosis Research Institute, London, UK and Elverum Central Hospital, Elverum, Norway) |
| 0443 | EFFICACY AND SAFETY PROFILE OF 220 MG DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING TOTAL HIP OR KNEE REPLACEMENT SURGERY WITH A HISTORY OF STROKE, TRANSIENT ISCHAEMIC ATTACK OR VENOUS THROMBOEMBOLISM O.E. Dahl, C. Francis, A.A. Kurth, N. Rosencher, M. Feuring, H. Noack, A. Clemens, B.I. Eriksson, J.A. Caprini (Thrombosis Research Institute, London, UK and Elverum Central Hospital, Elverum, Norway) |
| 0444 | LOW PLATELET GLYCOPROTEIN IB-POSITIVE MICROPARTICLES IN PATIENTS WITH CORONARY STENT THROMBOSIS G.L. Mendolicchio, C. Godino, D. Zavalloni, A. Colombo, Z.M. Ruggeri (Istituto Clinico Humanitas, Rozzano, Italy) |
| 0445 | YOUNG PATIENTS WITH STROKE, PFO (PATENT FORAMEN OVALE) AND THROMBOPHILIA C. Lodigiani, P. Ferrazzi, L. Librè, E. Morenghi, M. Minaudo, L.L. Rota, D. Mari (Ist Clinico Humanitas, Rozzano/Milan, Italy) |
| 0446 | HIGHER CIRCULATING ACTIVATED PROTEIN C (APC)/PC AND APC/FACTOR II RATIOS DURING ORAL ANTICOAGULANT THERAPY. INFLUENCE OF THE HAPLOTYPE 1 OF THE ENDOTHELIAL PROTEIN C RECEPTOR GENE F. España, S. Navarro, P. Medina, F. Ferrando, A. Vayá, Y. Mira, A. Estellés, F. España (Hospital Universitario La Fe, Valencia, Spain) |
| 0447 | LAC TESTING IN PATIENTS WITH INFLAMMATORY STATUS M.E. Schouwers, J. Delanghe, K. Devreese (Ghent University Hospital, Ghent, Belgium) |
| 0448 | SILENT BRAIN ABNORMALITIES IN THALASSEMIA INTERMEDIA: DIAGNOSTIC CONTRIBUTION OF POSITRON EMISSION TOMOGRAPHY A. Taher, K. Musallam, W. Nasreddine, A. Beydoun (American University of Beirut Medical Center, Beirut, Lebanon) |
| 0449 | REVERSAL OF THE ANTIHAEMOSTATIC EFFECTS OF RIVAROXABAN BY ACTIVATED FACTOR VII AND ACTIVATED PROTHROMBIN COMPLEX IN PRIMATES A. Gruber, U.M. Marzec, U. Buetehorn, S. Hanson, E. Perzborn (Oregon Health and Science University School of Medicine, Portland, USA) |
| 0450 | THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE GENETIC THROMBOPHILIC DEFECTS: A COMPARATIVE STUDY G. De Asis, L. Tse, J. Chan, K. Ramadan (University of British Columbia, Vancouver, Canada) |
| 0451 | ADAMTS13 LEVELS IN HIV INFECTED PATIENTS WITH AND WITHOUT TTP P.N. Badenhorst, M. Meiring, B. van Staden, W.J. Janse van Rensburg, H. Deckmyn (University of the Free State, Bloemfontein, South Africa) |
| 0452 | HIGH AVIDITY ANTICARDIOLIPIN ANTIBODIES ASSOCIATE WITH THROMBOSIS IN PATIENTS WITH ANTHIPHOSPHOLIPID SYNDROME G. Lobreglio, G.C. Giancarlo (A.O. “Card G Panico”, Tricase, Italy) |
| 0453 | THE USE OF INFERIOR VENA CAVAL FILTERS AT A DISTRICT GENERAL HOSPITAL IN THE UNITED KINGDOM N.B. Bhatnagar, J. Blundell (Royal Cornwall Hospital NHS Trust, Truro, United Kingdom) |
| 0454 | IDENTIFICATION OF MUTATIONS IN THE PROTEIN C GENE ASSOCIATED WITH THE RISK OF VENOUS TROMBOSIS F. España, P. Medina, S. Navarro, A. Vayá, F. Ferrando, M.T. Contreras, A. Estellés, F. España (Hospital Universitario La Fe, Valencia, Spain) |
| 0455 | ARE THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) POLYMORPHISMS DETERMINANTS OF THE TYPE OF ACUTE CORONARY SYNDROME? D. Tassies, M. Roque, J. Monteagudo, T. Martorell, A. Sionis, D. Arzamendi, M. Heras, J.C. Reverter (Hospital Clinic Barcelona, Barcelona, Spain) |
INFECTIOUS DISEASES, SUPPORTIVE CARE I
| 0456 | ORAL VALGANCICLOVIR AS EARLY PRE-EMPTIVE TREATMENT FOR CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE IN 45 PATIENTS |
|---|---|
| 0457 | INCIDENCE AND RISK FACTORS OF PROVEN OR PROBABLE INVASIVE FUNGAL INFECTIONS (IFI) IN 286 PATIENTS UNDERGOING RELATED OR UNRELATED ALLOGENEIC BONE MARROW TRANSPLANTATION |
| 0458 | ONCE-WEEKLY LIPOSOMAL AMPHOTERICIN B FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTION AFTER GRAFT VERSUS HOST DISEASE (GVHD) IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-SCT): A COMPARATIVE RETROSPECTIVE MONOCENTER STUDY |
| 0459 | INVASIVE ASPERGILLOSIS IN ACUTE MYELOID LEUKEMIA: REPORT OF SEIFEM-2008 MULTICENTER SURVEY |
| 0460 | RAPID DETECTION AND IDENTIFICATION OF PATHOGENS IN HEMATOONCOLOGICAL PATIENTS USING MOLECULAR TECHNIQUES S. Pekova, O. Mazal, J. Vydra, H. Kabickova, T. Kozak, S. Pekova (Na Homolce Hospital, Prague, Czech Republic) |
| 0461 | COMBINED QUANTITATIVE CMV PCR MONITORING WITH PREEMPTIVE ORAL VALGANCLOVIR IS EFFECTIVE IN PREVENTING SYMPTOMATIC CMV INFECTION IN ALLOGENEIC HAEMOPOIETIC TRANSPLANT RECIPIENTS S. Hewamana, B. Austen, K. Karunanithi, U. Mohite, N. Price, K. Wilson (UHW, Cardiff, United Kingdom) |
| 0462 | CANDIDEMIA IN PATIENTS WITH HEMAT0LOGICAL MALIGNANCIES: THE ROLE OF PROPHYLAXIS AND THE IMPORTANCE OF LOCAL EPIDEMIOLOGY IN TREATMENT M. Bastos Oreiro, M. Canales, R. De Paz Arias, A. Lopez de la Guia, P. Baltazar, M.J. Garcia Rodriguez, J. Garcia Rodriguez, F. Hernandez Navarro (Hospital La Paz, Madrid, Spain) |
| 0463 | MANAGEMENT OF FEBRILE NEUTROPENIA EPISODES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES BY USING THE MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER (MASCC) RISK INDEX A. Argyrou, M. Pergaminou, A. Galanopoulos, T. Marinakis, E. Michalis, }G. Gkortzolidis, N.I. Anagnostopoulos (“G.N.A. G.Gennimatas” General Hospital of Athens, Athens, Greece) |
| 0464 | SERUM N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN HAEMATOLOGICAL PATIENTS WITH NEUTROPENIC FEVER: A PROSPECTIVE COMPARISON WITH C-REACTIVE PROTEIN E. Jantunen, S. Hämäläinen, T. Kuittinen, I. Koivula, I. Matinlauri, T. Nousiainen, K. Pulkki, A. Juutilainen (Kuopio University Hospital, Kuopio, Finland) |
| 0465 | PALONOSETRON (ALOXI): A SINGLE-CENTER EXPERIENCE IN THE PREVENTION OF EMESIS IN PATIENTS AFFECTED BY HAEMATOLOGICAL MALIGNANCIES A.A. Assanelli, S. Agazzi, C. Soliman, F. Ciceri, V. Matozzo (San Raffaele Hospital, Milan, Italy) |
| 0466 | PROLONGED FOLLOW-UP OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES INFECTED BY HBV AND HCV S. Kulikov, T.S. Garmaeva, E. Mihailova, B. Sudarikov, P. Filatov, G. Savchenko (National Center for Hematology, Moscow, Russian Federation) |
| 0467 | COMPARISON BETWEEN FILGASTRIM AND PEG-FILGASTRIM IN REDUCING FEBRILE NEUTROPENIA AND MOBILIZING PBSC IN LYMPHOMA PATIENTS TREATED WITH DHAP OR R-DHAP L. Marbello, M. Riva, A. Molteni, A. Nosari, G. Nador, L. Gargantini, E. Morra (Niguarda Cà Granda Hospital, Milan, Italy) |
| 0468 | NATURAL HISTORY OF HEPATITIS E DURING THE COURSE OF HAEMATOLOGICAL MALIGNANCIES S. Tavitian, J.M. Peron, A. Huynh, J.M. Mansuy, F. Huguet, L. Ysebaert, M. Roussel, M. Attal, C. Recher (CHU Toulouse, Toulouse, France) |
| 0469 | FILGRASTIM DOSE HAS AN IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION Z. Peric, M. Kalac, S. Jurenec, V. Kovacevic, S. Bukovski-Simonoski,A. Tambic-Andrasevic, H. Minigo, B. Jaksic, R. Vrhovac (Clinical Hospital Merkur, Zagreb, Croatia) |
| 0470 | THE CONTRIBUTION OF NUTRITIONAL STATUS OF CHILDREN WITH MALIGNANCY TO MORBIDITY, MORTALITY AND THERAPY OUTCOMES T. Hassan (Zagazig University, Zagazig, Egypt) |
Print view ]
